BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Paradigms Foundation - ECPv6.18.0//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://paradigms.foundation X-WR-CALDESC:Events for Paradigms Foundation REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Europe/Paris BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20230326T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20231029T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20240331T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20241027T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20250330T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20251026T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20260329T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20261025T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20270328T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20271031T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260929T163000 DTEND;TZID=Europe/Paris:20260929T173000 DTSTAMP:20260923T162319Z CREATED:20260901T100648Z LAST-MODIFIED:20260923T162319Z UID:14730-1790699400-1790703000@paradigms.foundation SUMMARY:Live Webinar on Paediatric Multiple Sclerosis DESCRIPTION:Join this ParadigMS live webinar dedicated to Paediatric Multiple Sclerosis (MS) and explore expert perspectives on the challenges of recognising\, diagnosing and managing MS in children and adolescents. \n\n\n\nThe session will bring together leading experts to discuss current clinical considerations and provide practical insights relevant to neurologists and healthcare professionals involved in MS care. \n\n\n\nKey Highlights\n\n\n\n\nEpidemiology\, genetic and environmental factors in paediatric MS.\n\n\n\nDisease course\, smouldering disease and risk of persistent disability.\n\n\n\nNew diagnostic criteria and differential diagnosis\, including NMOSD and MOGAD.\n\n\n\nCSF\, imaging and blood biomarkers.\n\n\n\nNeuropsychological performance\, quality of life and psychological issues.\n\n\n\nPharmacological therapies and evolving treatment approaches.\n\n\n\nLong-term monitoring and support for younger patients and their families.\n\n\n\nQ&A on key clinical challenges.\n\n\n\n\nMore information & Learning Objectives to come soon \n\n\n\nFind out more about the speakers: \n\n\n\nSpeakers\n\n\n\n\nThais Armangué \n\n\n\nCarlo Pozzilli\n\n\n\n\nModerator\n\n\n\n\nValeria Pozzilli\n\n\n\n\nRegister\n\n\n\nThis session will be delivered live on Zoom. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nWhy participate?\n\n\n\n\nExplore the key clinical features of paediatric Multiple Sclerosis (MS)\n\n\n\nStrengthen diagnostic confidence in children and adolescents with suspected MS\n\n\n\nReview important differential diagnoses and challenges specific to paediatric-onset disease\n\n\n\nDiscuss current approaches to treatment selection and long-term disease management\n\n\n\nGain expert perspectives on monitoring disease activity and supporting care across the transition to adulthood\n\n\n\n\nWho should join?\n\n\n\n\nNeurologists and paediatric neurologists with an interest in Multiple Sclerosis\n\n\n\nMS specialists and neurologists in training\n\n\n\nNurses and other healthcare professionals involved in MS care\n\n\n\nHealthcare professionals involved in the diagnosis or management of paediatric demyelinating disorders\n\n\n\n\nQuestions and comments\n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\nTechnology used\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nDate and time\n\n\n\nThe session will be held on Tuesday\, 29th September 2026 from 16:30 to 17:30 CEST. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCarlo Pozzilli\n\n\n\n\nProfessor of Clinical Neuroscience at University of Rome “La Sapienza” \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThaìs Armangué\n\n\n\n\nHead of the Department and attending in the Paediatric Neuroimmunology Unit at SJD Barcelona Children’s Hospital \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nValeria Pozzilli\n\n\n\n\nNeurologist and researcher\, Queen Square MS Centre\, UCL Queen Square Institute of Neurology\, University College London\, United Kingdom \n\n\n\n\n\n\n\nRegistration\n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n \n\n\n\n\nRegister now\n\n\n\n\nFunding\n\n\n\nThis webinar was organized with the financial support of Roche. \n\n\n\nRoche has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-paediatric-multiple-sclerosis/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/09/PDMS-Live-webinar-banner-1080x655px_1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260905T083000 DTEND;TZID=Europe/Paris:20260905T134500 DTSTAMP:20260605T090440Z CREATED:20260603T142911Z LAST-MODIFIED:20260605T090440Z UID:14355-1788597000-1788615900@paradigms.foundation SUMMARY:ParadigMS Expert Meeting 2026 DESCRIPTION:Casa d’Este – Hotel Ferrara\, Italy\n\n\n\n\n\nPractical details\n\n\n\nDate: Saturday\, 5 September 2026Time: 08:30 -13:45Location: Casa d’Este – Hotel Ferrara\, ItalyAudience: ParadigMS expert members \n\n\n\nUpon invitation meeting only \n\n\n\nThe ParadigMS Expert Meeting 2026 will bring together international neurologists and Multiple Sclerosis (MS) experts to discuss current and emerging topics in demyelinating diseases. \n\n\n\nThe programme will focus on new therapies\, paediatric MS\, symptomatic treatment\, healthcare system impact on treatment choice\, disability progression\, BTK inhibitors\, and clinical management of Neuromyelitis Optica Spectrum Disorder (NMOSD)\, optic neuritis and MS. \n\n\n\nProgramme overview\n\n\n\n08:30–08:45Introduction to the meetingCelia Oreja-Guevara \n\n\n\n08:45–09:15New therapies in MGAndrew Chan\, Maura Pugliatti \n\n\n\n09:15–09:45Paediatric MSMagd Zakaria\, Carlo Pozzilli \n\n\n\n09:45–10:15Symptomatic therapies in Multiple SclerosisVeronica Popescu\, Bart Van Wijmeersch\, Carlo Pozzilli\, Melinda Magyari\, Patrick Vermersch \n\n\n\n10:15–10:45Coffee break \n\n\n\n10:45–11:20How healthcare system classification impacts treatment choice in Multiple SclerosisThomas Berger\, Tjalf Ziemssen\, Nikolaos Grigoriadis\, Magd Zakaria\, Melinda Magyari \n\n\n\n11:20–11:40Prognosis in Multiple SclerosisMaura Pugliatti \n\n\n\n11:40–12:00Uncovering Disability Progression in People with Multiple Sclerosis: A Practical GuideBart Van Wijmeersch\, ParadigMS Office team \n\n\n\n12:00–12:40Treatment landscape and approaches in the era of BTK inhibitors \n\n\n\n12:40–13:10Lunch \n\n\n\n13:10–13:30Diagnosis and clinical management of NMO/Optic Neuritis and MSKazuo Fujihara\, Celia Oreja-Guevara\, Melinda Magyari \n\n\n\n13:30–13:45ClosingCelia Oreja-Guevara \n\n\n\n\n \n\n\n\n\nThe ParadigMS Expert Meeting will be sponsored by Roche\, Sandoz and Sanofi URL:https://paradigms.foundation/event/paradigms-expert-meeting-2026-ferrara-italy/ LOCATION:Ferrara\, Italy ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/06/Castello-Estense.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260904T140000 DTEND;TZID=Europe/Paris:20260904T180000 DTSTAMP:20260901T123003Z CREATED:20260603T145017Z LAST-MODIFIED:20260901T123003Z UID:14377-1788530400-1788544800@paradigms.foundation SUMMARY:Scientific meeting: Multiple Sclerosis - Multiple Predictors in Disease Prognostication DESCRIPTION:The scientific meeting chaired by ParadigMS expert Maura Pugliatti will be exploring current and emerging predictors of disease progression in Multiple Sclerosis.\n\n\n\nRegistration\n\n\n\nParticipation is free of charge\, but registration is required as places are limited. Please complete the registration form to confirm your attendance. \n\n\n\n\nRegister to attend the in-person scientific meeting\n\n\n\n\nMeeting details\n\n\n\nDate: Friday\, 4 September 2026Time: 13:00-18:10Location: Palazzo Roverella\, Ferrara\, ItalyRegistration: Free of chargeCME accreditation: No CME credits available \n\n\n\nUnderstanding disease progression remains one of the greatest challenges in Multiple Sclerosis (MS) care. This scientific meeting will bring together leading international experts to examine the diverse factors that contribute to disease prognostication\, from clinical and biological markers to emerging technologies and predictive models. \n\n\n\nParticipants will explore current evidence on pathophysiology\, biomarkers\, genetic studies\, registries\, comorbidities\, imaging\, and decision-support systems\, while discussing how these insights may support more personalized management strategies for people living with MS. \n\n\n\nDepliant_MS&NO_September4_DEFDownload\n\n\n\nDownload the programme \n\n\n\nScientific committee\n\n\n\n\nMaura Pugliatti\n\n\n\nCaterina Ferri\n\n\n\nNicola Merli\n\n\n\nMassimiliano Castellazzi\n\n\n\n\nProgramme overview\n\n\n\nSession I\n\n\n\nPrognostication in Multiple Sclerosis: Pathogenesis\, Pathophysiology and Clinical Presentation \n\n\n\n14:00Multiple sclerosis progression: pathophysiology and measurementsCelia Oreja-Guevara (Spain) \n\n\n\n14:20Clinical predictors of disease progressionBart Van Wijmeersch (Belgium) \n\n\n\n14:40Biomarkers in predicting multiple sclerosis worseningLaura Airas (Finland) \n\n\n\n15:00Prognostication from genetic studiesSandra D’Alfonso (Italy) \n\n\n\n15:20Investigating disease prognosis through data collection: the Italian MS RegistryPietro Iaffaldano (Italy) \n\n\n\n15:40Microchimerism in multiple sclerosisMichele Rubini (Italy) \n\n\n\n16:00Discussion \n\n\n\nSession II\n\n\n\nPrognostication in Multiple Sclerosis: Evidence About Less Conventional Predictors \n\n\n\n16:20Prognostication from cerebrospinal fluid analysisMassimiliano Castellazzi (Italy) \n\n\n\n16:40Comorbidities in multiple sclerosis progressionCaterina Ferri (Italy) \n\n\n\n17:00The role of ultrasound in prognosis through the study of the optic nerveNicola Merli (Italy) \n\n\n\nSession III\n\n\n\nPrognostication in Multiple Sclerosis: Moving Towards Algorithms and Decisional Support Systems \n\n\n\n17:20Decisional support systems\, modelling and algorithmsMassimiliano Copetti (Italy) \n\n\n\n17:40Prognostication in multiple sclerosis: the PROMISING StudyMaura Pugliatti (Italy) \n\n\n\n18:00Discussion \n\n\n\n18:10Closing remarksMaura Pugliatti (Italy) \n\n\n\nWhy attend?\n\n\n\nThis meeting offers a comprehensive overview of established and emerging predictors of disease progression in Multiple Sclerosis\, bringing together expertise from clinical practice\, epidemiology\, genetics\, biomarker research and data science. Attendees will gain practical insights into how prognostic tools may support more informed treatment decisions and personalised patient care. \n\n\n\nUnder the auspices of\n\n\n\n\nParadigMS\n\n\n\nUniversity of Ferrara\n\n\n\nFerrara University Hospital\n\n\n\nFerrara Health District\n\n\n\nItalian Society of Neurology (SIN)\n\n\n\nItalian Association of Neuroepidemiology (AINEP)\n\n\n\n\nSponsorships URL:https://paradigms.foundation/event/scientific-meeting-multiple-sclerosis-multiple-predictors-in-disease-prognostication/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/06/Palazzo.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260627T080000 DTEND;TZID=Europe/Paris:20260627T170000 DTSTAMP:20260511T075638Z CREATED:20260511T075637Z LAST-MODIFIED:20260511T075638Z UID:14295-1782547200-1782579600@paradigms.foundation SUMMARY:ParadigMS at EAN 2026 DESCRIPTION:We are excited to announce that ParadigMS will be present at the 12th Congress of the European Academy of Neurology (EAN) 2026\, taking place from June 27 to 30\, 2026\, at Palexpo in Geneva\, Switzerland. \n\n\n\nJoin us throughout the congress to discover the latest ParadigMS educational initiatives and resources dedicated to advancing care in Multiple Sclerosis (MS)\, Neuromyelitis Optica Spectrum Disorder (NMOSD)\, and MOG Antibody Disease (MOGAD). \n\n\n\nVisit our team in the Neurohood\, the dedicated networking and collaboration area for neurological organisations and partners. At our booth\, attendees will be able to explore: \n\n\n\n\nPeer-reviewed educational slide decks\n\n\n\nEACCME® accredited e-learning programmes\n\n\n\nScientific updates and practical clinical resources\n\n\n\nNew initiatives supporting multidisciplinary neurological care\n\n\n\n\nThe overarching theme of EAN 2026 is “Brains\, Bytes & Beyond: Tech in Neurology”\, highlighting how technological innovation and artificial intelligence are transforming neurological practice\, research\, and patient care. \n\n\n\nWe look forward to connecting with neurologists\, researchers\, healthcare professionals\, and partners from around the world in Geneva. \n\n\n\nFor more information about the congress\, visit: \n\n\n\n\nEAN Congress 2026 URL:https://paradigms.foundation/event/paradigms-at-ean-2026/ LOCATION:Palexpo Genova ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/05/Congress-of-the-European-Academy-of-Neurology-EAN-2026-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260613T000000 DTEND;TZID=Europe/Paris:20260613T235959 DTSTAMP:20260616T140459Z CREATED:20251216T103224Z LAST-MODIFIED:20260616T140459Z UID:12647-1781308800-1781395199@paradigms.foundation SUMMARY:Annual MS Meeting 2026 DESCRIPTION:Saturday\, June 13th – morning session\n\n\n\n\n\n\n\nOptic Neuritis Unveiled: Clinical and Imaging Perspectives\n\n\n\nIrish College\, Leuven\n\n\n\nThe Belgian Study Group for Multiple Sclerosis (BSGMS) and ParadigMS Foundation are pleased to announce the Annual MS Meeting 2026\, a scientific meeting for the Belgian MS community and allied healthcare professionals. \n\n\n\nThis year’s meeting\, entitled “Optic Neuritis Unveiled: Clinical and Imaging Perspectives\,” will focus on optic neuritis as a key clinical entity in multiple sclerosis and related disorders. The programme will combine clinical expertise with advanced imaging approaches\, highlighting how evolving diagnostic tools can support earlier diagnosis\, improved prognostication\, and optimized patient management. \n\n\n\nPictures from the meeting (by DAVID PLAS PHOTOGRAPHY) \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nScientific Programme \n\n\n\nThe meeting will feature three keynote lectures delivered by internationally recognized experts\, followed by interactive case discussions and clinical conclusions. This is an in-person meeting and no livestream will be available. \n\n\n\n\n\n\n\n \n\n\n\nAbout the co-chairs and the keynotes speakers\n \n \n \n \n About the speakers\n \n \n \n About the co-Chairs\n \n \n \n \n \n\n\n\n\n\n\n\nAxel Petzold (UK) is a consultant neurologist at the National Hospital for Neurology and Neurosurgery\, Queen Square\, and at Moorfields Eye Hospital in London. His clinical and research work focuses on multiple sclerosis and optic neuritis. He is a Fellow of the Royal College of Physicians\, the Royal College of Ophthalmologists\, and the Royal College of Pathologists. Over the years\, he has been involved in a number of collaborative initiatives\, including serving as Chair for Neuro-Ophthalmology within the European Reference Networks for Rare Diseases. He has also helped develop integrated care pathways between his NHS Hospital Trusts. Prof Petzold has published widely in peer-reviewed journals and has supervised and mentored fellows and students from different countries. He remains committed to careful clinical practice\, collaborative research\, and supporting the next generation of clinicians and scientists. \n\n\n\n\n\n\n\n\n\nAnne-Catherine Chapelle (Belgium) is a neuro-ophthalmologist and pediatric ophthalmologist at the University Hospital of Liège\, where she is involved in both clinical practice and academic activities. She completed a neuro-ophthalmology fellowship in London under the supervision of Professor Gordon Plant\, gaining advanced expertise in the diagnosis and management of complex neuro-ophthalmic disorders\, including inflammatory and demyelinating diseases of the visual pathway. She subsequently completed a doctoral thesis focused on retinal ganglion cell evaluation in ischemic optic neuropathies\, with particular attention to structural and functional correlations. Her clinical and research interests center on optic nerve disorders and the use of retinal imaging\, notably optical coherence tomography (OCT)\, as a biomarker in neurological diseases. \n\n\n\n\n\n\n\n\n\n\n\n\n\nJette Lautrup Frederiksen (Denmark) is Professor of Neurology\, Senior Consultant\, MD and Doctor of Medical Sciences (DMSc) at University of Copenhagen based on thesis “A prospective Study of Acute Optic Neuritis: Clinical\, MRI. CSF\, Neurophysiological and HLA Findings”. She has 40 years of research experience in the clinical\, imaging\, neurophysiological and biomedical aspects of optic neuritis\, multiple sclerosis and neuro-ophthalmology. She is the founder of the Multiple Sclerosis Clinic at Copenhagen University Hospital Rigshospitalet Glostrup\, Denmark and head of the Optic Neuritis Clinic there. Since 2011 she has been Professor in Optic Neuritis in relation to Multiple Sclerosis at the University of Copenhagen. She is by Scholar GPS ranked No. 2 within the category Optic Neuritis lifelong and has authored more than 300 publications in international scientific journals. \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nBelgian Study Group for Multiple Sclerosis \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParadigMS Foundation \n\n\n\n\n\n\nProf. Bénédicte Dubois (Belgium) is an internationally recognised neurologist and multiple sclerosis expert. She is Head of the Department of Neurology at University Hospitals Leuven\, Head of the Laboratory for Neuroimmunology\, and part-time Full Professor at the Faculty of Medicine of KU Leuven\, where she also leads the Research Group Experimental Neurology and oversees the medical clerkship centres. Alongside her leadership roles\, she is a pioneer of interdisciplinary MS care and precision medicine in Belgium\, and her translational research focuses on the neuroimmunological and genetic mechanisms underlying MS\, supported by a unique longitudinal patient database. She is also actively involved in multiple internal and external committees dedicated to education and scientific research. \n\n\n\nProf. Bart Van Wijmeersch (Belgium) is a neurologist specialised in multiple sclerosis and Associate Professor of Neurology at the University of Hasselt\, affiliated with the Biomedical Institute (BIOMED). He is Medical Director of the Rehabilitation and MS Center in Pelt\, where he leads a multidisciplinary MS team delivering comprehensive patient care. His academic and clinical work bridges immunological\, biomarker\, MRI\, electrophysiological\, and rehabilitation research in MS\, combining pre-clinical models\, clinical studies\, and translational approaches. In addition to his research and clinical leadership\, he plays an active educational role within the faculties of medicine and physiotherapy. He is a member of the Belgian Study Group of Multiple Sclerosis\, founding President of ParadigMS\, and serves on advisory boards for pharmaceutical companies active in MS research. In recognition of his scientific contributions\, he received an honorary award from the Flemish Government in 2019. \n\n\n\n \n\n\n\n \n \n \n \n\n\n\nAbstracts of the keynotes\nAxel Petzold (UK) – Clinical Aspects of Optic Neuritis \n\n\n\nOptic neuritis (ON) is an inflammatory disorder of the optic nerve and a common cause of visual loss\, particularly in young and middle-aged adults. Clinically\, ON presents with subacute unilateral visual loss\, periocular pain exacerbated by eye movement\, impaired colour vision\, and visual field defects. Although many patients recover high-contrast visual acuity\, residual deficits in contrast sensitivity\, colour perception\, visual fields\, and visual fatigue are common. Clinically a common cause in a Caucasian population is multiple sclerosis (MS). Some clinical features such as bilateral involvement\, severe visual loss\, poor recovery\, or absence of pain should prompt urgent evaluation for other ON subgroups. \n\n\n\nThe clinical spectrum of ON is heterogeneous. MS-associated ON (MS-ON) remains frequent in neurological practise. IN MS-ON visual recovery is typically good. In contrast\, aquaporin-4 antibody-associated ON (AQP4-ON) is typically more severe\, may be bilateral\, and carries a high risk of permanent visual disability and future relapses. Myelin oligodendrocyte glycoprotein antibody-associated ON (MOG-ON) often presents with marked optic disc swelling and exquisite corticosteroid responsiveness. The relapse risk in MOG-ON varies\, with about half of all cases being monophasic. Accurate early phenotyping of ON is therefore central to prognosis and long-term management. \n\n\n\nDiagnosis is clinical\, supported by magnetic resonance imaging (MRI)\, serum antibody testing (AQP4-IgG and MOG-IgG)\, and optical coherence tomography (OCT). Acute management commonly includes high-dose corticosteroids to accelerate recovery\, with escalation therapies such as plasma exchange or IVIG considered in severe or refractory cases. Secondary prevention strategies depend on aetiology and relapse risk\, particularly in antibody-mediated disease and in patients at high risk of developing MS. \n\n\n\nBeyond acute treatment\, clinical care must address visual rehabilitation\, mental health burden\, and relapse surveillance. Persistent pain\, visual fatigue\, and anxiety about recurrence are frequent but under-recognised sequelae. Despite advances in immunotherapy and diagnostics\, substantial global variability remains in access to timely imaging\, antibody testing\, specialist care\, and relapse-preventive therapy. \n\n\n\nON is therefore both a neurological emergency and a window into systemic inflammatory disease. Optimising clinical outcomes requires early recognition\, aetiology-driven management\, structured follow-up\, and equitable access to specialist services. \n\n\n\nAnne-Catherine Chapelle (Belgium) – Seeing Optic Neuritis Through Optical Coherence Tomography: a new biomarker \n\n\n\nSince the revised McDonald criteria now include the optic nerve as a fifth topographical location\, careful and precise neuro-ophthalmologic examination has become mandatory. Accurate diagnosis of optic neuritis relies on a comprehensive assessment\, including optical coherence tomography (OCT). This technique enables precise\, non-invasive quantification of the peripapillary retinal nerve fiber layer and the ganglion cell layer. In this keynote\, we will review the evidence linking OCT findings to the diagnosis of optic neuritis\, visual outcomes\, and disease activity\, as well as its role in monitoring disease evolution. These data highlight the growing relevance of OCT in both clinical practice and research. \n\n\n\nJette Latrup Frederiksen – Optic neuritis as a window to the brain: MRI and functional VEP \n\n\n\nThe 2024 revision of the McDonald criteria introduced a major change by including the optic nerve as the fifth anatomical location demonstrating dissemination in space (DIS)\, thereby enhancing the diagnostic sensitivity of MS. Not only MRI of the optic nerve\, but also VEP and OCT can confirm affection of the optic nerve. Thus structural as well as functional examinations of the visual pathways are important. This talk will mainly focus on imaging aspects (MRI of the optic nerve and brain) beyond OCT together with functional testing including VEP and multifocal VEP. \n\n\n\n\nVenue: The Irish College\, Leuven\, and Parking details \n \n \n \n \n Address of the venue\n \n \n \n About this Irish College\n \n \n \n About the parking\n \n \n \n \n \n\n\nLocation: Paridaensinstituut \n\n\n\nAddress : Janseniusstraat 1\, 3000 Leuven \n\n\n\nTelephone  : 016 31 04 30 \n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\nThe Irish College Leuven was founded in 1607 and is one of the oldest Irish colleges on the European continent. It was established to educate Irish priests at a time when religious training was restricted in Ireland. Over the centuries\, the College became an important intellectual and cultural hub\, closely linked to the University of Leuven\, and played a key role in preserving Irish scholarship and heritage. Today\, it stands as a historical symbol of the long-standing academic and cultural ties between Ireland and Belgium. \n\n\n\n\n\nThe parking space is available near the venue. \n\n\n\nAccess & Parking \n\n\n\nBethlehem parking: \n\n\n\nFree parking is available at Bethlehem Parking\, Leuven. The address is Redingenstraat 21\, 3000 Leuven\, approximately a 5-minute walk from the venue.Access code is: 15953#. \n\n\n\nGroup parking: Q-Park Heilig Hart \n\n\n\nAddress : Naamsestraat 102\, 3000 Leuven (≈ 10-minute walk to Irish College) \n\n\n\n \n\n\n\n \n \n \n \n\n\n\nFAQ \n\nHow can I register for the event?\nSimply click on REGISTRATION button you can see above this section and then select your admission ticket category \n\n\n\n\nCan I bring a guest?\nAbsolutely! You can register up to 5 persons per session\, if they are also healthcare professionals with a focus on neurology \n\n\n\n\nHow can I get updates or notifications about the meeting?\nStay connected with all updates and news by subscribing to the ParadigMS Foundation webpage: https://paradigms.foundation/ \n\n\n\n\nWill there be food and beverages provided?\nYes\, we provide a welcome coffee\, a coffee break and a networking lunch with a variety of drinks. \n\n\n\n\nWhat if I need to cancel my registration?\nIf you need to cancel your registration\, please send a message to learning@paradigms.foundation. \n\n\n\n\nIs there a dress code for the meeting?\nWe recommend wearing smart casual attire. \n\n\n\n\nWill the Annual MS meeting be live streamed?\nNo\, the live sessions of the meeting are not live streamed and available only for onsite participants. \n\n\n\n\nWho can I contact for additional information?\nIf you have any questions or need further information about either of the two learning experiences\, please feel free to reach out to us at learning@paradigms.foundation. \n\n\n\n\nWill there be a written report from the sessions?\nYes\, the ParadigMS Secretariat is planning to have a medical writer on site who will be tasked with producing a written report from both sessions. \n\n\n\n\nWill any of the sessions be recorded on video for later viewing?\nYes\, the keynotes will be video and audio recorded and will be made available on ParadigMS.foundation. You will need to create a Member account to have access to the recording (conditions to join as a member apply). \n\n\n\n\n\n\nSponsorships\nIn return for their sponsorship\, our sponsors receive visibility and can register a limited number of their staff to join the Meeting. Sponsors are not involved in the elaboration of the programme and presentations.  \n\n\n\n \n \n \n \n Our gold sponsors\n \n \n \n Our bronze sponsors\n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n \n \n \n \n\n\nInterested to join as a sponsor? Please contact ParadigMS at secretariat@paradigms.foundation \n\n\n\n\n \n\n\n\nOrganized by URL:https://paradigms.foundation/event/annual-ms-meeting-2026/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/12/AMS2026-PROD-banner-1080x655px-01.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260527T173000 DTEND;TZID=Europe/Paris:20260527T183000 DTSTAMP:20260513T082814Z CREATED:20260513T082653Z LAST-MODIFIED:20260513T082814Z UID:14311-1779903000-1779906600@paradigms.foundation SUMMARY:Live Webinar on the Early intervention in Multiple Sclerosis: the role of high-efficacy therapies in long-terms outcomes DESCRIPTION:Join ParadigMS Foundation for a live webinar exploring the evolving role of early intervention and high-efficacy therapies in Multiple Sclerosis (MS). This webinar will review current evidence on long-term clinical outcomes\, treatment strategies\, and practical considerations for neurologists involved in MS care. \n\n\n\nKey Highlights\n\n\n\n\nReview of current evidence on high-efficacy therapies and long-term outcomes \n\n\n\nPractical insights into treatment selection and therapeutic sequencing \n\n\n\nClinical perspectives from internationally recognized MS experts \n\n\n\nInteractive session designed for neurologists and MS healthcare professionals \n\n\n\nLive webinar with automated translation available for international participants \n\n\n\nOpportunity to explore evolving approaches to long-term MS management\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister to access the webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are:\n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Wednesday\, 27 May 2026 from 5:30 to 6:30 p.m. CEST. \n\n\n\nInvited Speakers\n\n\n\n\n\n\n\nTjalf Ziemssen\n\n\n\nProfessor of Clinical Neuroscience at University Clinic Carl-Gustav Carus in Dresden  \n\n\n\n\n\n\n\nBart Van Wijmeersch\n\n\n\nAssociate Professor of Neurology at the University of Hasselt  \n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Sandoz. \n\n\n\nSandoz has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-the-early-intervention-in-multiple-sclerosis-the-role-of-high-efficacy-therapies-in-long-terms-outcomes/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/05/LAU-PR3-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260429T173000 DTEND;TZID=Europe/Paris:20260429T183000 DTSTAMP:20260413T155125Z CREATED:20260413T084357Z LAST-MODIFIED:20260413T155125Z UID:13900-1777483800-1777487400@paradigms.foundation SUMMARY:Live Webinar on the long-term efficacy and safety of anti-CD20 therapies DESCRIPTION:Anti-CD20 therapies have become a central component in the management of Multiple Sclerosis (MS)\, with growing evidence supporting their sustained use. In this live webinar\, Celia Oreja-Guevara and Patrick Vermersch will review long-term efficacy and safety data\, translating current evidence into practical insights for neurologists involved in treatment decisions. \n\n\n\n \n\n\n\nKey Highlights\n\n\n\n\nReview long-term efficacy data of anti-CD20 therapies in Multiple Sclerosis (MS) \n\n\n\nAssess safety profiles with extended treatment exposure \n\n\n\nDiscuss risk–benefit considerations in long-term disease management \n\n\n\nExplore real-world evidence and its implications for clinical practice \n\n\n\nAddress monitoring strategies and patient selection over time \n\n\n\nGain expert perspectives on optimizing treatment decisions\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister to access the webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are:\n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Wednesday\, 29 April 2026 from 5:30 to 6:30 p.m. CET. \n\n\n\nInvited Speakers\n\n\n\n\n\n\n\nCelia Oreja-Guevara\n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. As an investigator\, she has participated in a number of MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. Currently\, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency. \n\n\n\n\n\n\n\nPatrick Vermersch\n\n\n\nVice-president of Research in the fields of Life and Health Sciences at the University of Lille \n\n\n\nPatrick Vermersch studied medicine at Lille University Hospital (France)\, where he graduated in Neurology. Between 1990 and 1994 he pursued his training in basic research fields\, mainly in cellular biology\, obtaining a PhD addressing biochemical abnormalities associated with Alzheimer’s and other neurodegenerative diseases. He also conducted research related to the characterization of post-transcriptional anomalies of tau proteins. His research interests then turned to multiple sclerosis (MS). \n\n\n\nProf. Patrick Vermersch is head of one of the University of Lille’s departments of Neurology which deals with MS and other neuroinflammatory diseases. The department is primarily concerned with neuroimmunology and markers of disease evolution. \n\n\n\nProf. Patrick Vermersch is currently vice-president of research in the fields of Life and Health Sciences at the University of Lille. In 2000\, he and colleagues created the first MS network in northern France to improve MS care and research. His current areas of interest are prognostic markers in MS and neuroimmunology in general. He participates in many treatment protocols for MS. He has authored or co-authored approximately 380 scientific papers. His H-index (Web of Science) is 54. \n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Neuraxpharm. \n\n\n\nNeuraxpharm has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-the-long-term-efficacy-and-safety-of-anti-cd20-therapies/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/04/LAU-PROD-banner-live-webinar-sessions-260429-1200x627px.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260310T163000 DTEND;TZID=Europe/Paris:20260310T173000 DTSTAMP:20260605T115256Z CREATED:20260226T135458Z LAST-MODIFIED:20260605T115256Z UID:13431-1773160200-1773163800@paradigms.foundation SUMMARY:Live Webinar on Pregnancy and Lactation in Multiple Sclerosis DESCRIPTION:Pregnancy and lactation in multiple sclerosis (MS) remain critical and often complex phases in a woman’s disease journey. Questions around relapse risk\, treatment interruption\, breastfeeding safety\, and long-term outcomes require careful\, individualized decision-making. With evolving evidence and updated recommendations\, clinicians must balance disease control with maternal and infant safety. \n\n\n\nIn this live webinar\, Celia Oreja-Guevara and Melinda Magyari will discuss practical\, real-world approaches to managing MS before\, during\, and after pregnancy. \n\n\n\n \n\n\n\nKey Highlights\n\n\n\n\nA clear overview of relapse risk and disease activity during pregnancy and the postpartum period.\n\n\n\nGuidance on treatment planning before conception and strategies around treatment interruption or continuation.\n\n\n\nPractical considerations for improving patient experience and long-term outcomes.\n\n\n\nLive Q&A to address your clinical questions\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister here to join the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are: \n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Tuesday\, 10th March 2026 from 16:30 to 17:30 CET. \n\n\n\nInvited Speakers\n\n\n\n\n\n\n\nCelia Oreja-Guevara\n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. As an investigator\, she has participated in a number of MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. Currently\, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency. \n\n\n\n\n\n\n\nMelinda Magyari\n\n\n\nDirector of the Danish Multiple Sclerosis Registry and Consultant neurologist at department of Neurology\, Rigshospitalet\, Denmark \n\n\n\nHer major research area is in multiple sclerosis and other inflammatory disorders of the central nervous system with a special interest in the changing epidemiology and gender differences. Using nationwide population-based data sources her research addresses questions on comorbidities\, reproductive issues\, risk factors and socioeconomic consequences in multiple sclerosis. She is involved in pharmacoepidemiological studies investigating the effectiveness and long-term safety of disease modifying therapies. \n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Roche. Roche has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-pregnancy-and-lactation-in-multiple-sclerosis/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/02/LAU-PROD-banner-live-webinar-sessions-260310-1200x627px.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260129T200000 DTEND;TZID=Europe/Paris:20260129T210000 DTSTAMP:20260120T094718Z CREATED:20251119T105946Z LAST-MODIFIED:20260120T094718Z UID:12496-1769716800-1769720400@paradigms.foundation SUMMARY:Live Webinar on the Clinical management of NMOSD in Belgium DESCRIPTION:Neuromyelitis optica spectrum disorder (NMOSD) is a rare but highly disabling autoimmune disease that predominantly affects the optic nerves and spinal cord. Delayed or missed diagnosis can have life-changing consequences\, but evolving diagnostic criteria and new targeted therapies are reshaping outcomes for people living with NMOSD. \n\n\n\nIn this webinar\, Professor Vincent van Pesch will discuss practical\, real-world approaches to diagnosing and managing NMOSD in Belgium\, from the first suspicious attack to long-term treatment decisions and patient follow-up. The webinar will be introduced and moderated by Doctor  Melissa Cambron. \n\n\n\nRISIV/INAMI Accreditation: The number 26002105 has been assigned to this activity. \n\n\n\nActivity status: Application submitted – Verification by the NHIF. \n\n\n\nKey Highlights\n\n\n\n\nA clear overview of how NMOSD is recognised and differentiated from other neurological conditions such as MS.\n\n\n\nAn introduction to how clinicians typically confirm the diagnosis in everyday practice.\n\n\n\nGeneral principles for managing acute attacks and supporting long-term care.\n\n\n\nHow patient needs\, treatment access\, and care pathways influence clinical decision-making in Belgium.\n\n\n\nPractical considerations for improving patient experience and long-term outcomes.\n\n\n\nLive Q&A to address your clinical questions\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister here to join the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are: \n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Thursday\, 29th January 2026 from 20:00 to 21:00 CET. \n\n\n\nInvited Speaker\n\n\n\n\n\n\n\nProfessor Vincent van Pesch\n\n\n\nProfessor of Neurology and Associate Head of the Neurology department of the Cliniques Universitaires Saint-Luc \n\n\n\nDr Van Pesch obtained his medical degree in 1999 from Université Catholique de Louvain and then completed his PhD thesis in neuroimmunology in 2003. He served as neurology resident at Department of Neurology\, Saint-Luc Hospital and then progressed in positions from Adjunct Clinical Head to Associate Clinical Head and finally to Adjunct Chief of Neurology Department at Cliniques Universitaires Saint-Luc. He is also responsible for a number of other services within the same place such as coordination and supervision of the neurophysiology unit and supervision and teaching of electroencephalography and evoked potentials to neurology residents. \n\n\n\nAt Université Catholique de Louvain\, Dr Van Pesch is a Profssor of Neurology and is responsible for teaching neuroimmunology and cerebrospinal fluid/neurochemistry analysis as he is the Principal investigator at Neurochemistry Unit at UCL. \n\n\n\nDr Van Pesch also greatly contributes to scientific publications and has over 200 published papers in a number of renowned journals. He is also co-editor of Frontiers Neurology\, section of Multiple Sclerosis and neuroimmunology and section of Neuroepidemiology and also Co-editor of the Acta Neurologica Belgica. \n\n\n\n\n\n\n\nProfessor Melissa Cambron\n\n\n\nMD\, PhD\, neuroinflammatory specialist at AZ Sint-Jan Bruges \n\n\n\nMelissa Cambron\, MD\, PhD\, is a neuroinflammatory specialist at AZ Sint-Jan Bruges\, a position she has held since 2018\, and is affiliated with Ghent University. She completed her specialization and obtained her PhD at the Vrije Universiteit Brussel (VUB). Dr. Cambron further expanded her clinical and academic expertise through a one-year fellowship in neurology at CHRU Lille under the supervision of Professor Patrick Vermersch. Her clinical and research interests focus on neuroinflammatory and neuroimmunological disorders\, including neuromyelitis optica spectrum disorders. \n\n\n\nRegistration\n\n\n\nRegistration is required and can be finalized either via the button located at the top of this page or through the following button below. \n\n\n\n\nRegistration\n\n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Alexion. Alexion has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-the-clinical-management-of-nmosd-in-belgium/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/11/LAU-PROD-banner-live-webinar-sessions-260129-1080x655px-02-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251216T160000 DTEND;TZID=Europe/Paris:20251216T170000 DTSTAMP:20251127T133242Z CREATED:20251114T135924Z LAST-MODIFIED:20251127T133242Z UID:12467-1765900800-1765904400@paradigms.foundation SUMMARY:Live Webinar on MRI & diagnostic criteria DESCRIPTION:MRI & diagnostic criteria \n\n\n\nDuring this live webinar\, Prof. Cristina Granziera and Prof. Celia Oreja-Guevara\, MS and Neuroimmunology experts\, will share key insights on MRI and diagnostic criteria in multiple sclerosis clinical practice. \n\n\n\nJoin us for an interactive and up-to-date session exploring how MRI guides the diagnosis\, differential diagnosis and monitoring of Multiple Sclerosis (MS). Our speakers will walk you through the MRI features that matter most in clinical decision-making\, explaining how lesion characteristics support dissemination in space and time within the MS diagnostic framework. \n\n\n\nCelia Oreja-Guevara will also introduce the new diagnostic criteria\, highlighting what changes for clinicians and how MRI can facilitate earlier and more accurate diagnosis. \n\n\n\nThe webinar will further explore the prognostic value of MRI\, and participants will be introduced to advanced MRI techniques as well as emerging biomarkers. \n\n\n\nFinally\, the webinar will address MRI red flags and differential diagnosis\, helping clinicians distinguish MS from common mimics and avoid misdiagnosis . \n\n\n\nThis session brings together core principles\, new diagnostic perspectives\, and advanced imaging insights to support clinicians in making confident\, evidence-based decisions in MS care. \n\n\n\nThroughout the webinar\, participants will have the opportunity to ask questions directly to the experts\, ensuring a dynamic and clinically relevant discussion. \n\n\n\nKey Highlights\n\n\n\n\nExpert insights from two leading MS specialists\n\n\n\nPractical review of MRI markers essential for MS diagnosis\n\n\n\nOverview of the new diagnostic criteria and their impact on practice\n\n\n\nPrognostic MRI indicators linked to disability progression\n\n\n\nIntroduction to advanced techniques and new biomarkers\n\n\n\nMRI red flags and differential diagnosis strategies\n\n\n\nLive Q&A to address your clinical questions\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister here to join the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are: \n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Tuesday\, 16th December 2025 from 16:00 to 17:00 CET. \n\n\n\nParadigMS Speakers\n\n\n\n\n\n\n\nProfessor Cristina Granziera \n\n\n\nCo-CEO of the Research Center for Clinical Neuroimmunology and Neuroscience Basel\, Professor at the University of Basel\, and senior consultant neurologist at the University Hospital of Basel  \n\n\n\n\n\n\n\n\n\n\n\nProfessor Celia Oreja-Guevara\n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\nRegistration\n\n\n\nRegistration is required and can be finalized either via the button located at the top of this page or through the following button below. \n\n\n\n\nRegistration\n\n\n\n\nFunding\n\n\n\nThis webinar is funded with ParadigMS own funds. No other sponsors have been invited to support this webinar. URL:https://paradigms.foundation/event/live-webinar-on-mri-diagnostic-criteria/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/11/LAU-PROD-banner-live-webinar-sessions-251216-1200x627px.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251204T020000 DTEND;TZID=Europe/Paris:20251204T030000 DTSTAMP:20251113T145712Z CREATED:20251113T143637Z LAST-MODIFIED:20251113T145712Z UID:12451-1764813600-1764817200@paradigms.foundation SUMMARY:ParadigMS in Dubai for the Pre-MENACTRIMS Symposium DESCRIPTION:ParadigMS is pleased to announce its participation in the upcoming MENACTRIMS Congress by organizing a Pre-MENACTRIMS Symposium\, taking place on Thursday\, 4th December in Dubai\, United Arab Emirates at the Intercontinental Hotel Festival City. \n\n\n\n\n\n\n\n\nVisit the ParadigMS pre-MENACTRIMS Symposium website\n\n\n\n\nFree Make sure to register for free access to the Pre-MENACTRIMS Symposium \n\n\n\n\n\n\n\nMeet and discuss with the ParadigMS team on Friday 5th and Saturday 6th December at the ParadigMS booth during MENACTRIMS Congress\, where attendees can discover our latest content\, including peer-reviewed slide decks\, accredited e-learning modules\, and expert-driven educational resources in MS\, NMOSD\, and MOGAD. \n\n\n\n\n\n\n\n\n\n\n\nWith thanks to our sponsor\, who supports this event without any involvement in the elaboration of the presentations. URL:https://paradigms.foundation/event/paradigms-in-dubai-for-the-pre-menactrims-symposium/ END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251106T130000 DTEND;TZID=Europe/Paris:20251106T200000 DTSTAMP:20251208T130443Z CREATED:20250616T152302Z LAST-MODIFIED:20251208T130443Z UID:11707-1762434000-1762459200@paradigms.foundation SUMMARY:ParadigMS Regional MS Symposium DESCRIPTION:The ParadigMS Regional MS Symposium in Belgrade\, co-organised by the Serbian Neuroimmunology Society and the ParadigMS Foundation\, was specifically designed to address the clinical and educational needs of the Balkan region. The programme offered a deep dive into current challenges and evolving concepts in multiple sclerosis (MS) care\, including newly proposed diagnostic criteria\, radiological markers (such as PRLs and the central vein sign)\, cerebrospinal fluid analysis\, and the role of aging in MS. \n\n\n\nAttendees engaged in high-level discussions on detecting disease progression\, emerging biomarkers\, and updated approaches to NMOSD management. The final session highlighted the practical implications of generics and biosimilars\, as well as innovative therapeutic strategies including B-cell and CAR-T therapies. \n\n\n\nWith a combination of expert presentations\, dynamic panel debates\, and Q&A sessions\, the symposium was designed to support neurologists in translating complex scientific developments into clinical practice. \n\n\n\n \n\n\n\nParadigMS after movie\n\n\n\nThe symposium brought together a strong regional community of 120 neurologists and experts\, and the active participation throughout the sessions made for rich exchanges and practical takeaways. We are grateful to all speakers and attendees for contributing to such a dynamic atmosphere. To relive some of the highlights moments from Belgrade’s ParadigMS Regional MS Symposium\, we invite you to watch the after movie below. \n\n\n\n\n\n\n\nScientific Programme\n\n\n\n \n\n\n\nParadigMS Regional MS Symposium_ParadigMS and Serbian NeuroImmuno Society_ProgrammeDownload\n\n\n\nThe upcoming MS Symposium in Belgrade promises a rich programme of scientific exchange and clinical insights. Visit the official website to explore the line-up of expert speakers and stay informed about the agenda\, themes\, and registration. \n\n\n\n\nFind out more URL:https://paradigms.foundation/event/paradigms-regional-ms-symposium/ ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2025/05/Regional-Symposium-Balkans.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251028T170000 DTEND;TZID=Europe/Paris:20251028T180000 DTSTAMP:20251111T104723Z CREATED:20251007T091908Z LAST-MODIFIED:20251111T104723Z UID:12322-1761670800-1761674400@paradigms.foundation SUMMARY:Live webinar on Real-Life Experiences with biosimilars DESCRIPTION:Live webinar on Real-Life Experiences with Biosimilars \n\n\n\nDuring this live webinar\, Prof. Tjalf Ziemssen and Prof. Jelena Drulovic\, MS and neuroimmunology experts\, will share their real-life experiences with biosimilars in multiple sclerosis clinical practice. \n\n\n\nJoin us for an insightful webinar exploring how biosimilars in multiple sclerosis (MS) are being integrated into clinical practice. Learn how biosimilars are used and how the switch is prepared from both a person with MS and physician perspective. \n\n\n\nWe’ll discuss: \n\n\n\n\nWhat biosimilars are and how regulatory agencies like the EMA and FDA ensure their safety and equivalence.\n\n\n\nPatient perspectives — addressing concerns about efficacy\, safety\, and the psychological impact of switching treatments.\n\n\n\nClinician challenges — balancing payer pressure\, communication with patients\, and the importance of transparency.\n\n\n\nSystem-level impact — how biosimilars can generate cost savings and expand treatment access.\n\n\n\nReal-world examples — case vignettes highlighting both successful transitions and the influence of the nocebo effect.\n\n\n\n\nDiscover the science\, the communication strategies\, and the real-world experiences driving the future of multiple sclerosis care. \n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister here to join the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are: \n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Tuesday\, 28th October 2025 from 17:00 to 18:00 CEST. \n\n\n\nParadigMS Speakers\n\n\n\n\n\n\n\nProfessor Tjalf Ziemssen\n\n\n\nProfessor of Clinical Neuroscience at University Clinic Carl-Gustav Carus in Dresden \n\n\n\n\n\n\n\nProfessor Jelena Drulovic\n\n\n\nProfessor of Neurology at the Faculty of Medicine\, University of Belgrade \n\n\n\nModerator\n\n\n\nStefaan de Corte\, ParadigMS General Manager \n\n\n\nRegistration\n\n\n\nRegistration is required and can be finalized either via the button located at the top of this page or through the following button below. \n\n\n\n\nRegistration\n\n\n\n\nFunding\n\n\n\nThis webinar is organised with the financial support of Sandoz. \n\n\n\nSandoz has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-real-life-experiences-with-biosimilars/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/10/LAU-PROD-banner-live-webinar-sessions-251028-1080x655px-banner.jpg ORGANIZER;CN="ParadigMS":MAILTO:secretariat@paradigms.foundation END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250924T080000 DTEND;TZID=Europe/Paris:20250926T170000 DTSTAMP:20250715T114939Z CREATED:20250714T140503Z LAST-MODIFIED:20250715T114939Z UID:12106-1758700800-1758906000@paradigms.foundation SUMMARY:ParadigMS presence at ECTRIMS 2025 DESCRIPTION:ParadigMS at ECTRIMS 2025 – See You in Barcelona!We’re excited to be present at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 24–26 September 2025 in Barcelona\, Spain. \n\n\n\nJoin us to explore the latest in MS education\, access our newest publications\, and connect with the experts driving our e-learning and clinical content. Whether you’re interested in diagnostic updates\, treatment strategies\, or translational research\, ParadigMS is here to support your learning journey. \n\n\n\n🧠 Visit our booth to discover how we’re advancing MS education—for neurologists\, by neurologists. URL:https://paradigms.foundation/event/paradigms-presence-at-ectrims-2025/ ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2025/07/Activity-3.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250906T080000 DTEND;TZID=Europe/Paris:20250906T140000 DTSTAMP:20250827T083547Z CREATED:20250710T130138Z LAST-MODIFIED:20250827T083547Z UID:12036-1757145600-1757167200@paradigms.foundation SUMMARY:ParadigMS Experts Meeting DESCRIPTION:On Saturday\,6th September\, ParadigMS will convene an Expert Meeting in Athens\, assembling top specialists in multiple sclerosis to review and discuss educational materials on MS treatment and care. \n\n\n\nThe participation is on invitation only. \n\n\n\nThe detailed agenda of the meeting you may find below: \n\n\n\n\n8:30 – 8:40 Welcome and introduction to the agenda\n\n\n\n8:40 – 8:45 Overview of presentations that will be published on the ParadigMS website \n\n\n\nSafety tests within the clinical management of multiple sclerosis \n\n\n\nB-Cell therapies in the treatment of multiple sclerosis \n\n\n\nDiagnosis and clinical management of NMOSD\n\n\n\n8:45 – 10:15 Presentations – Part I\n\n\n\nBody fluid markers \n\n\n\nUse of AI and technology in MS clinical care pathways \n\n\n\nReal life experiences with generics and biosimilars\n\n\n\nSymptomatic therapies in multiple sclerosis (Part I\, Spasticity\, Ataxia\, Mobility\, Tremor\, Pain\, Tingling)\n\n\n\n\n10:15 – 10:45 BREAK   \n\n\n\n\n10:45 – 11:45 Presentations – Part II\n\n\n\nSymptomatic therapies in multiple sclerosis (Part II\, Vertigo and dizziness\, Dysphagia\, Autonomic dysfunction\, Bladder and Bowel\, Sexual problems\, Fatigue\, Cognitive problems\, Emotional problems)\n\n\n\nBrain health in multiple sclerosis \n\n\n\n11:45 – 12:00 Articles – Status\n\n\n\nIn production: How to Uncover Subtle Progression in MS.\n\n\n\nPublished: Current state of knowledge on role of microglia in health and disease: implications for the management of MS\n\n\n\nPublished: Review paper: The use of generics and biosimilars in the treatment of multiple sclerosis\n\n\n\nProposed new topic for a paper: Diagnosis and clinical management of NMO/Optic Neuritis and MS\n\n\n\n12:00 – 12:20 Projects – Status\n\n\n\nProposal: Quality of care in MS: A comparative study of European quality indicators and implementation practices\n\n\n\nPrognosis in Multiple Sclerosis\n\n\n\n12:20 -13:00 E-learnings – status\n\n\n\nPublished: Beyond EDSS: How to Monitor Disease Progression in Multiple Sclerosis.\n\n\n\nOngoing: Beyond EDSS: How to Monitor Disease Progression in Multiple Sclerosis – instruction videos\n\n\n\n\n13:00 LUNCH \n\n\n\n \n\n\n\nMeeting Sponsors:\n\n\n\nThe ParadigMS Experts Meeting is sponsors by Sandoz and Sanofi. URL:https://paradigms.foundation/event/paradigms-expert-meeting/ ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2025/07/Activity-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250905T160000 DTEND;TZID=Europe/Paris:20250905T203000 DTSTAMP:20250829T072821Z CREATED:20250702T093409Z LAST-MODIFIED:20250829T072821Z UID:12018-1757088000-1757104200@paradigms.foundation SUMMARY:Scientific Meeting: Continued medical education on translational neuro-immunology: Current and potential molecular targets for MS\, NMOSD and MOGAD therapies. DESCRIPTION:Join us in Athens on Friday\, 5th September 2025\, for an engaging scientific meeting that brings together leading minds in neuroimmunology. \n\n\n\nCo-organised by ParadigMS and the Hellenic Academy of Neuroimmunology\, this one-day programme will explore the latest translational insights into molecular targets for MS\, NMOSD\, and MOGAD therapies. \n\n\n\nFrom B-cells and astrocytes to the endocannabinoid and sphingosine systems\, internationally renowned experts will guide you through science and its clinical applications. \n\n\n\nWhether you’re a clinician or a researcher\, this is a unique opportunity to deepen your understanding\, exchange ideas\, and shape future treatment strategies—all in the historic setting of the University of Athens. \n\n\n\nPlease find and download the programme: \n\n\n\nParadigMS Scientific Meeting in Athens_ProgrammeDownload\n\n\n\nDownload the Scientific Meeting brochure\, including programme\, speakers\, sponsors. \n\n\n\nFinal ProgramDownload\n\n\n\nTo register – please click in the button below. You will be redirected into the registration platform: \n\n\n\n\nRegister\n\n\n\n\nThere is no registration fee. \n\n\n\n\n\n\n\n\n\nSpeakersSponsorsLocal secretariat\n\nAiras LauraProfessor of Neuroimmunology\, University of Turku\, Finland \n\n\n\nBakirtzis ChristosNeurologist\, 2nd Department of Neurology\, Aristotle University of Thessaloniki\, AHEPAUniversity Hospital of Thessaloniki\, Greece \n\n\n\nBoziki Marina-KleopatraAssistant Professor of Neurology\, AristotleUniversity of Thessaloniki\, Greece \n\n\n\nDeisenhammer FlorianProfessor of Neurology\, Medical Universityof Innsbruck\, Austria \n\n\n\nEvangelopoulos Eleftheria-MariaAssociate Professor of Neurology- Neurochemistry\, National and Kapodistrian University of Athens\, Greece \n\n\n\nGrigoriadis NikolaosProfessor of Neurology\, AristotleUniversity of Thessaloniki\, Head of the 2nd Department of Neurology\, AHEPAUniversity Hospital of Thessaloniki\, Greece \n\n\n\nHartung Hans-PeterProf. em. Dr.\, Department of Neurology\, Heinrich-Heine-University\, Düsseldorf\,Germany \n\n\n\nIliopoulos IoannisProfessor of Neurology\, University of Thrace\, Head of the Department of Neurology\, University of Thrace\, UniversityHospital of Alexandroupolis\, GreeceKontoulis Zinais Consultant Anaesthetist–Pain Medicine\,Athens\, Greece \n\n\n\nMagyari MelindaConsultant\, MD\, PhD\, Professor\, DanishMultiple Sclerosis Center\, The Danish Multiple Sclerosis Registry CopenhagenUniversity Hospital\, Rigshospitalet\, Denmark \n\n\n\n \n\n\n\nOreja-Guevara CeliaProfessor-Vice Chair of Neurology\, Head of Multiple Sclerosis Center\, UniversityHospital San Carlos Madrid\, Spain \n\n\n\nPozzilli CarloProfessor of Clinical Neuroscience\, University of Roma La Sapienza\, Italy \n\n\n\nProbert LesleyDirector of Research\, Head of the Department of Immunology\, Head of theLaboratory of Molecular Genetics\, Hellenic Pasteur Institute\, Athens\, Greece \n\n\n\nStathopoulos Panos-AlexiosAssistant Professor of Neurology and Neuroimmunology\, National andKapodistrian University of Athens\, Greece \n\n\n\nVan Wijmeersch BartAssociate Professor of Neurology\,University of Hasselt\, Belgium \n\n\n\nVermersch PatrickProfessor\, Vice-President of Research\, Head of the Departments of Neurology\,University of Lille\, France \n\n\n\nZakaria MagdProfessor of Neurology\, Ain Shams University Cairo\, President of the EgyptianMS\, Egyptian Society of Multiple Sclerosis\, Egypt \n\n\n\nZiemssen TjalfProfessor of Clinical Neuroscience\, Head of the Multiple Sclerosis Center andNeuroimmunological Laboratory\, Director of Division of Neurometabolism\, UniversityClinic Carl-Gustav Carus\, Dresden\, Germany \n\n\n\n\n\n\n\n\n\n\n\nwww.globalevents.grThessaloniki: 50 A Stadiou Str.\, 55534\, Pylaia\, ThessalonikiΤ +30 2310 247743\, Ε info@globalevents.grAthens: 2 Valestra str. & 168 A. Syngrou Av.\, 17671\, AthensΤ +30 210 3250260\, Ε athens@globalevents.gr URL:https://paradigms.foundation/event/scientific-meeting-continued-medical-education-on-translational-neuro-immunology-current-and-potential-molecular-targets-for-ms-nmosd-and-mogad-therapies/ LOCATION:Alkis Argyriadis Amphitheatre – National and Kapodistrian University of Athens\, Panepistimiou St. 30\, Athens\, Greece ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/07/Banners_Linkedin--scaled.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250621T080000 DTEND;TZID=Europe/Paris:20250624T120000 DTSTAMP:20250617T083928Z CREATED:20250417T115722Z LAST-MODIFIED:20250617T083928Z UID:11637-1750492800-1750766400@paradigms.foundation SUMMARY:ParadigMS at EAN 2025 in Helsinki DESCRIPTION:We are excited to announce that ParadigMS will be present at the 11th European Academy of Neurology (EAN) Congress\, taking place from June 21 to 24\, 2025\, at the Messukeskus Expo and Convention Centre in Helsinki\, Finland .​ \n\n\n\nVisit us in the Neurohood\, booth #20\, a dedicated space within the congress designed for networking and collaboration among neurological organisations. At our booth\, you can explore our latest educational materials\, including peer-reviewed slide decks and EACCME® accredited E-learning programs\, all aimed at enhancing patient care in MS\, NMOSD\, and MOGAD.​ \n\n\n\nThe overarching theme of EAN 2025 is “Neurology within Society”\, focusing on the intersection of neurological practice and societal factors . This aligns with ParadigMS’ mission to bridge scientific research and clinical practice through high-quality medical education.​ \n\n\n\nFor more information about the EAN 2025 Congress\, including registration details and the full program\, please visit the official EAN website: \n\n\n\nWe look forward to connecting with you in Helsinki! \n\n\n\n\nEAN Website URL:https://paradigms.foundation/event/join-paradigms-at-ean-2025-in-helsinki/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/04/LAU-PROD-banner-EAN-congress-2025-1080X655px-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250614T090000 DTEND;TZID=Europe/Paris:20250614T133000 DTSTAMP:20250712T131938Z CREATED:20250110T113537Z LAST-MODIFIED:20250712T131938Z UID:10998-1749891600-1749907800@paradigms.foundation SUMMARY:Belgian Annual MS Meeting 2025 DESCRIPTION:The Belgian Study Group for Multiple Sclerosis and ParadigMS Foundation has proudly held the Annual MS Meeting 2025\, a premier event for the Belgian MS community. \n\n\n\nThis year’s meeting featured two distinguished keynote speakers sharing their expertise on the theme “Clarifying the evolving role of imaging in the diagnosis of Multiple Sclerosis.“ \n\n\n\nProf. Pietro Maggi (UCL\, Belgium) talked about new diagnostic criteria for MS\, focusing on the critical role of MRI markers. His session will explore how advanced imaging techniques can improve diagnostic precision. \n\n\n\nProf. Christine Lebrun-Frenay (University of Nice\, France) presented the 2024 revision of the McDonald Criteria for diagnosing multiple sclerosis (MS)\, which incorporates new advancements in understanding MS pathobiology and diagnostic tools. Key updates include the addition of the optic nerve as a diagnostic site\, new radiological markers (CVS and PRLs)\, the use of CSF kappa-free light chains\, and expanded guidelines for diverse patient populations\, including paediatric cases and those with comorbidities. \n\n\n\nProf. Bénédicte Dubois (President of the BSGMS) and Prof. Bart Van Wijmeersch (Board Member\, ParadigMS) were chairing each session\, setting the stage for insightful discussions and case presentations. \n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\nProgrammeSpeakers and ChairsAbstracts\n\n09:00 – 09:30Registration and welcome coffee09:30 – 09:45Welcome and introduction to the topic by Bénédicte Dubois (President BSGMS) and Bart Van Wijmeersch (Board Member ParadigMS)09:45 – 10:15Keynote lecture – Pietro Maggi (UCL\, Belgium) to present the topic: inclusion of novel imaging biomarkers in the 2024 revisions of the McDonald criteria.10:15-10:45Clinical case presentations and discussions:Presenters: Serena Borrelli\, Hôpital ErasmeSarah Cappelle\, UZ LeuvenSarah Laurent\, CHU Saint-Pierre & National MS Center Melsbroek10:45 – 11:05Coffee break and networking11:05 – 11:35Keynote lecture – Christine Lebrun-Frenay (University of Nice Cote d’Azur\, France) – to discuss the translation of 2024 MS criteria for asymptomatic individuals into clinical practice: From RIS to MS.11:35 – 12:05Clinical case presentations and discussions:Presenters: Guy Laureys\, UZ GentAntonia Lefter\, Universiteit AntwerpenMiguel D’Haeseleer\, UZ Brussel & National MS Center Melsbroek12:05 – 12:15Conclusions12:15 – 12:45 BSGMS’ General Assembly (Members only)12:15 -13:30Networking lunch\n\n\n\n\n\nKey Speakers\n\n\n\n\n\n\n\nProf. Christine Lebrun Frenay\, MD PhD\, FAAN\n\n\n\nDr. Christine Lebrun Frenay\, MD PhD\, FAAN\, is a Professor of Neurology and Oncologist. She is head of the inflammatory neurological disorders clinical research unit and MS center at the University of Nice Cote d’Azur. She is a member of the French Neurological Society and French MS Society (SFSEP)\, in which she was president and of the European and American Academies of Neurology. In 2008\, she described the first cohort of a subclinical form of MS. Subsequently\, she co-founded with American\, European\, and Turkish colleagues the RIS Consortium\, which expanded worldwide to collect a unique\, extensive patient cohort. Her research interest includes therapeutical and MRI studies in MS with a specific implication in the description of Radiologically Isolated Syndrome (RIS). She is the co-editor of recommendations in MS for the French MS Society (vaccines\, infections\, and DMTs). She is participating in numerous clinical trials and research studies with international publications in neuroinflammatory diseases. She is a member of several editorial boards of scientific journals and scientific boards and is involved in medical evaluations for MS patients’ associations.She was nominated in 2018 for the executive committee of the ECTRIMS\, the French Association for MS Research (ARSEP)\, received in 2020\, the Excellence Price of the Cote d’Azur University\, The French Neurological Society\, and 2023 member of the McDonald Committee \n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nProf. Pietro Maggi\, MD PhD\n\n\n\nDr. Pietro Maggi is specialised in the diagnosis and treatment of multiple sclerosis (MS). He is an Associate professor of clinical neurology at the Université Catholique de Louvain (UCLouvain) and a Neurologist at Cliniques Universitaires Saint-Luc. \n\n\n\nDr Maggi earned his MD from the University of Florence (Florence\, Italy) and his PhD in neuroscience from the same university\, in collaboration with the National Institutes of Health (Bethesda\, US). His training includes a doctoral fellowship at the NIH in the lab of Dr Daniel Reich (director of the Translational Neuroradiology Section\, NINDS)\, and a residency in neurology performed at the Erasme University Hospital in Brussels and at the Lausanne University Hospital in Lausanne (clinical-research ECTRIMS fellowship). \n\n\n\nHis clinical-research activity focuses on characterizing and modeling the pathogenesis of MS using advanced magnetic resonance imaging (MRI) methods. Thanks to several collaborations with other MS-research groups in EU and US\, Dr Maggi’s lab at UCLouvain aims to combine advanced and more established imaging\, laboratory and clinical data in order to improve MS diagnosis\, prognosis and\, ultimately\, to improve our understanding of MS pathophysiology. \n\n\n\n\n\n\n\nChairs\n\n\n\n\n\n\n\nProf. Bénédicte Dubois\n\n\n\nSince the beginning of my career I have been fascinated by multiple sclerosis (MS). I have gained both clinical and scientific expertise on this condition and have set up a research group that enjoys international recognition and that plays a leading role in the field. \n\n\n\nI performed my clinical training as neurologist under supervision of professor H. Carton in Leuven and professor A. Thompson and G. Giovannoni in London\, UK. In 2000 I obtained a PhD\, entitled The disease-promoting role of gelatinase B/MMP-9 in inflammation of the central nervous system\, under the guidance of professor G. Opdenakker (Rega Institute\, KU Leuven). Since then\, I developed a career in which personalized or precision medicine can be considered keywords. \n\n\n\nAt the clinical level\, and inspired by my visit in London\, I launched the concept of interdisciplinary outpatient clinics in Belgium. Central to this initiative is not only the provision of expertise from various medical or paramedical disciplines\, but above all the flexible and dynamic nature of this advice\, based on the individual’s needs at a specific moment. This idea was subsequently adopted by the MS Center in Melsbroek\, and further adapted in the form of a RIZIV convention (TMST – Transmuraal MS Team). \n\n\n\nWith regard to my scientific activities\, and as head of the Laboratory for Neuroimmunology at KU Leuven\, I focus on translational research in MS\, more specifically on the neuroimmunology and genetic architecture of the susceptibility and the heterogeneity of MS. I have set up a database containing clinical and genetic data of more than 1400 MS patients. In 700 of these patients\, longitudinal follow-up over many years is available\, which makes this database rather unique and precious. My lab has been successful in obtaining funding (e.g. Horizon2020\, FWO\, BOF\, Progressive Alliance NMSS)\, and in participating to leading international (IMSGC\, Horizon2020) and national (e.g. FWO-WOG\, Universiteit Hasselt\, Universiteit Antwerpen) collaborations. \n\n\n\nBesides clinical and research activities focused on MS\, I am also head of the department of Neurology at the University Hospitals Leuven\, part-time full professor and head of the medical clerkships centers of the Faculty of Medicine at KU Leuven\, head of the Research Group Experimental Neurology\, and member of several internal and external commissions related to education and scientific research. \n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nProf. Bart Van Wijmeersch\n\n\n\nBart Van Wijmeersch is a neurologist specialized in Multiple Sclerosis. He is medical director of the Rehabilitation and MS Center in Pelt where he leads the multidisciplinary MS-team. Furthermore\, he is an associate professor of Neurology at the University of Hasselt\, affiliated with the Biomedical Institute\, where he’s involved in pre-clinical as well as the clinical research on MS at the biomedical institute (BIOMED). He has a supporting role in all the immunological research on blood- and CSF samples of persons with MS and in EAE-animal models\, as well as in the rehabilitation research at REVAL. Immunological\, Biomarker\, MRI\, Electrophysiological and Rehabilitation research in MS come together in this way. He has an educational role in the faculty of medicine and physiotherapy. \n\n\n\nHe’s a member of the Belgian Study Group of Multiple Sclerosis\, first President of ParadigMS and a member of advisory boards of different pharmaceutical companies with interest in Multiple Sclerosis. \n\n\n\nAs acknowledgment of his scientific work\, he received an honorary award of the Flemish government in the summer of 2019. \n\n\n\n\n\n\n\n \n\n\n\n\n\nAbstracts of talk \n\n\n\nThe inclusion of novel imaging biomarkers in the 2024 revisions of the McDonald criteria. \n\n\n\nThe proposed revisions of the McDonald criteria include new susceptibility-based imaging biomarkers – the “central vein sign” and “paramagnetic rim lesions” – and recognize the importance of the optic nerve evaluation in the MS diagnostic work-up. Overall\, the addition of these pathologically-specific imaging biomarkers increases MS diagnostic accuracy\, potentially allowing faster diagnosis and earlier treatment. \n\n\n\n\n\n\n\nDiagnostic criteria during the presymptomatic phase of multiple sclerosis. \n\n\n\nRadiologically isolated syndrome (RIS) represents the initial visible phase in the spectrum of multiple sclerosis (MS). RIS is often found incidentally in asymptomatic individuals who exhibit typical lesions in the brain and/or spinal cord\, indicating autoimmune inflammatory demyelination. The updated 2023 RIS criteria aim to ensure an accurate and timely diagnosis due to various imaging mimics that resemble RIS. In the newly revised 2024 McDonald criteria\, RIS patients with additional characteristics\, such as positive CSF and susceptibility MRI biomarkers\, are classified as having MS. The two sets of criteria can be exclusive and need to be prospectively compared head-to-head. \n\n\n\n\n\n\n\n\n\nFAQSponsorsLocation\n\n\nWhen and where is the event taking place?\n\nThe 2025 Belgian Annual MS Meeting organised by the Belgian Study Group for Multiple Sclerosis and the ParadigMS Foundation\, will take place on Saturday\, 14 June 2025\, at 9am\, in the Faculty Club in Leuven.\n\n\n\n\n\nHow can I register for the event?\n\nSimply click on REGISTER button you can see above this section when available.\n\n\n\n\n\nIs there a registration fee?\n\nThis learning experience is offered for free only to BSGMS members\, neurology residents and MS nurses in Belgium\, all other categories should pay a fee of 40 eur. Registration is mandatory and seats are limited.\n\n\n\n\n\nWill there be any networking opportunities?\n\nThe coffee breaks environment will offer plenty of networking opportunities. \n\n\n\n\n\nAre there any accommodations nearby?\n\nThe Venue is located nearby convenient accommodation options for participants:\n\n Begijnhof Hotel**** (located next to Faculty Club)\n\n\n\n Martins Klooster Hotel****\n\n\n\n Penta Hotel****\n\n\n\n\n\n\n\nIs there parking available at the venue?\n\nThe venue provides free parking for participants.\n\n\n\n\n\nCan I bring a guest?\n\nYou can register a person\, if they are also healthcare professionals with a focus on neurology.\n\n\n\n\n\nHow can I get updates or notifications about the event?\n\nStay connected with all updates and news by subscribing to the ParadigMS Foundation webpage: https://paradigms.foundation/ \n\n\n\n\n\nIs there a dress code for the event?\n\nWe recommend wearing smart casual attire.\n\n\n\n\n\nWill there be food and beverages provided?\n\nYes\, we provide a welcome coffee\, water and lunch provided with a variety of drinks.\n\n\n\n\n\nWhat if I need to cancel my registration?\n\nIf you need to cancel your registration\, please send a message to learning@paradigms.foundation.\n\n\n\n\n\nHow can I become a sponsor of the event?\n\nIf you wish to become a sponsor of this event\, please send a message to learning@paradigms.foundation. \n\n\n\n\n\nWho can I contact for additional information?\n\nIf you have any questions or need further information about the learning experience\, please feel free to reach out to us at learning@paradigms.foundation.\n\n\n\n\n\nWhat if organisers need to cancel the event?\n\nThe Annual MS Meeting is organised by the Belgian Study Group for Multiple Sclerosis and the ParadigMS Foundation. The organiser reserves the right to cancel the event at any time due to unforeseen circumstances. In that case\, registrants will be notified by email and no compensation can be claimed.\n\n\n\n\n\nWill this symposium be live streamed?\n\nNo\, the two live sessions of the Annual MS Meeting are not live streamed and available only for onsite participants.\n\n\n\n\n\nWho can register for one of the sessions?\n\nThe Annual MS Meeting is open for neurologists\, radiologists\, neurology and radiology residents and MS nurses in Belgium. If you do not fall within this category\, please ask for prior approval to the ParadigMS secretariat before registering. If you register without prior approval and are not within the welcomed categories\, the organisers reserve the right to cancel your registration. In case of cancellation\, you will be notified. You can contact us via learning@paradigms.foundation.\n\n\n\n\n\n\n\n\nOur Gold sponsors: \n\n\n\n\n\n\n\n \n\n\n\nOur Bronze sponsors: \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFaculty Club \n\n\n\nAddress: \n\n\n\n•Groot Begijnhof 14\, 3000 Leuven \n\n\n\n•http://www.facultyclub.be/ \n\n\n\n•Phone number: 016329500 \n\n\n\nParking : \n\n\n\n•The parking space is available near the venue. \n\n\n\n•The code for the parking will be provided prior to the event. \n\n\n\nAccommodation: \n\n\n\nThe Venue is located nearby convenient accommodation options for participants: \n\n\n\n\nBegijnhof Hotel**** (located next to Faculty Club)\n\n\n\nMartins Klooster Hotel****\n\n\n\nPenta Hotel****\n\n\n\n\n\n\n \n\n\n\nMedia Partner: \n\n\n\n\n\n\n\nPictures from the Meeting (by DAVID PLAS PHOTOGRAPHY)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nY\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDAVID PLAS PHOTOGRAPHY URL:https://paradigms.foundation/event/annual-ms-meeting-2025/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/01/AMS-Banner-save-the-date-1080X655px-05.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250521T160000 DTEND;TZID=Europe/Paris:20250521T170000 DTSTAMP:20251119T104514Z CREATED:20250324T143000Z LAST-MODIFIED:20251119T104514Z UID:11452-1747843200-1747846800@paradigms.foundation SUMMARY:Live webinar on Differential diagnosis and management of NMOSD. DESCRIPTION:Live webinar on Differential diagnosis and management of NMOSD.\n\n\n\nIn this live webinar\, Prof. Celia Oreja-Guevara and Prof. Melinda Magyari\, MS and neuroimmunology experts\, will provide a comprehensive update on the diagnosis and treatment of neuromyelitis optica spectrum disorder (NMOSD). \n\n\n\nThe session will cover key clinical features\, revised diagnostic criteria\, antibody testing\, imaging characteristics\, and current treatment strategies—including relapse management and long-term therapies. Recent advances in biologic treatments and their clinical implications will also be discussed. \n\n\n\nDesigned for neurologists and MS specialists\, this webinar offers practical insights to help differentiate NMOSD from MS and improve decision-making in clinical practice. \n\n\n\nRegister\n\n\n\nThis session will be delivered live on Zoom\, offering practical insights on the differential diagnosis and management of NMOSD. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nWhy participate?\n\n\n\n\nGain clarity on how to distinguish NMOSD from MS in clinical practice\n\n\n\nUnderstand the latest diagnostic criteria and how to apply them\n\n\n\nExplore evidence-based strategies for relapse prevention and treatment\n\n\n\nLearn about the role of antibody testing\, MRI\, and OCT in diagnosis and monitoring\n\n\n\nStay current on newly approved and investigational therapies in NMOSD\n\n\n\n\nWho should join?\n\n\n\n\nNeurologists with an interest in multiple sclerosis treatments\n\n\n\nNeurologists in training\n\n\n\nNurses involved in MS patient care\n\n\n\nPatient representatives\n\n\n\n\nQuestions and comments\n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\nTechnology used\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nDate and time\n\n\n\nThe session will be held in English on Wednesday\, 21th May 2025 from 16:00 to 17:00 CEST. \n\n\n\nOur Speakers\n\n\n\n\n\n\n\nProf. Celia Oreja-Guevara\n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid. \n\n\n\n\n\n\n\n\n\n\n\nProf. Melinda Magyari\n\n\n\nDirector of the Danish Multiple Sclerosis Registry. \n\n\n\n\n\n\n\n\n\nModerator\n\n\n\nStefaan De Corte\, General Manager\, ParadigMS \n\n\n\nRegistration\n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n \n\n\n\n\nRegister now\n\n\n\n\nFunding\n\n\n\nThis webinar is organised with the financial support of Alexion. Alexion has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-differential-diagnosis-and-management-of-nmosd/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/03/LAU-PROD-banner-live-webinar-sessions-250521-1080X655px-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250422T160000 DTEND;TZID=Europe/Paris:20250422T170000 DTSTAMP:20250327T145625Z CREATED:20250324T123337Z LAST-MODIFIED:20250327T145625Z UID:11445-1745337600-1745341200@paradigms.foundation SUMMARY:Live webinar on B-cell therapies in the treatment of multiple sclerosis. DESCRIPTION:This live webinar explores the role of B-cell therapies in the treatment of multiple sclerosis\, focusing on current clinical evidence\, practical use in daily care\, and evolving treatment strategies. Expert perspectives will highlight key considerations for optimizing patient outcomes. \n\n\n\nRegister\n\n\n\nThe webinar will be delivered live on Zoom\, offering practical insights on the on B-cell therapies in the treatment of multiple sclerosis. Whether you are already using B-cell therapies in your practice or seeking to deepen your understanding\, this webinar will provide useful clinical insights and an opportunity to reflect on evolving treatment strategies. \n\n\n\n\nRegister for the live webinar\n\n\n\n\n \n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nWhy participate?\n\n\n\n\nReview current evidence supporting B-cell therapies in MS treatment.\n\n\n\nExamine clinical decision-making around patient selection and timing.\n\n\n\nDiscuss practical challenges in the use of B-cell therapies and explore solutions.\n\n\n\n\nWho should join?\n\n\n\n\nNeurologists with an interest in multiple sclerosis treatments\n\n\n\nNeurologists in training\n\n\n\nNurses involved in MS patient care\n\n\n\nPatient representatives\n\n\n\n\nQuestions and comments\n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\nTechnology used\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nDate and time\n\n\n\nThe webinar will be held in English on Tuesday\, 22nd April 2025 from 16:00 to 17:00 CET. \n\n\n\nOur Speakers\n\n\n\n\n\n\n\nProf. Celia Oreja-Guevara \n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid. \n\n\n\n \n\n\n\n\nAbout Celia Oreja-Guevara\n\n\n\n\n\n\n\n\n\n\n\n\nProf. Patrick Vermersch \n\n\n\nVice-president of Research in the fields of Life and Health Sciences at the University of Lille \n\n\n\n \n\n\n\n\nAbout Patrick Vermersch\n\n\n\n\n\n\n\n\n\n\nModerator\n\n\n\nStefaan De Corte\, General Manager\, ParadigMS \n\n\n\nRegistration\n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n \n\n\n\n\nRegister now\n\n\n\n\n \n\n\n\nFunding\n\n\n\nThis webinar is organised with the financial support of Neuraxpharm. Neuraxpharm has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-b-cell-therapies-in-the-treatment-of-multiple-sclerosis/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/03/LAU-PROD-banner-live-webinar-sessions-250422-1080X655px.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250325T150000 DTEND;TZID=Europe/Paris:20250325T160000 DTSTAMP:20250225T114714Z CREATED:20250212T101611Z LAST-MODIFIED:20250225T114714Z UID:11236-1742914800-1742918400@paradigms.foundation SUMMARY:Live Webinar on New diagnostic criteria for Multiple Sclerosis DESCRIPTION:New diagnostic criteria for MS \n\n\n\nJoin us for an insightful webinar on the latest advancements in MS diagnostics. This session will explore new diagnostic criteria\, emerging tools\, and their practical applications in improving early detection and patient management. \n\n\n\nThis webinar is designed for neurologists\, trainees\, and healthcare professionals involved in MS care. Don’t miss this opportunity to gain valuable insights from leading experts in the field! \n\n\n\nRegister\n\n\n\nThis session will be delivered live on Zoom\, offering practical insights on the safety tests in clinical management of MS. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nWhy participate?\n\n\n\n\nLearn about an overview of new diagnostic criteria for MS.\n\n\n\nDiscover best practices.\n\n\n\nListen to real-world case studies explaining the diagnostic evolution.\n\n\n\n\nWho should join?\n\n\n\n\nNeurologists with an interest in multiple sclerosis treatments\n\n\n\nNeurologists in training\n\n\n\nNurses involved in MS patient care\n\n\n\nPatient representatives\n\n\n\n\nQuestions and comments\n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\nTechnology used\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nDate and time\n\n\n\nThe session will be held in English on Tuesday\, 25th March 2025 from 15:00 to 16:00 CET. \n\n\n\nAbstract\n\n\n\nThe diagnosis of multiple sclerosis (MS) continues to evolve with advancements in imaging\, biomarkers\, and clinical guidelines. Accurate and early diagnosis is crucial for timely intervention and optimized patient care. This webinar explores the latest MS diagnostic criteria\, highlighting key updates\, their clinical application\, and how they impact treatment decisions. \n\n\n\nOur Speakers\n\n\n\n\n\n\n\nProf. Celia Oreja-Guevara\n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\n\nAbout Celia Oreja-Guevara\n\n\n\n\n \n\n\n\n\n\n\n\nProf. Bassem Yamout\n\n\n\nProfessor of Neurology and Director of the Neurology Institute at Harley Street Medical Center in Abu Dhabi \n\n\n\n\nAbout Bassem Yamout\n\n\n\n\nModerator\n\n\n\nStefaan De Corte\, General Manager\, ParadigMS \n\n\n\nRegistration\n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n\nRegister now\n\n\n\n\nPlease note: this is a live webinar primarily for neurologists from Europe\, the Middle-East and North-Africa. Should you know a colleague from other regions who would be interested in the topic – kindly share the registration link and invite them to join.  The event is free of charge\, but registration is required. \n\n\n\nFunding\n\n\n\nThis webinar is funded with ParadigMS own funds. No other sponsors have been invited to support this webinar. URL:https://paradigms.foundation/event/live-webinar-on-new-diagnostic-criteria-for-ms/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/02/LAU-PROD-banner-live-webinar-sessions-250325-1080x655px-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250306T163000 DTEND;TZID=Europe/Paris:20250306T173000 DTSTAMP:20250212T073348Z CREATED:20250110T080416Z LAST-MODIFIED:20250212T073348Z UID:11004-1741278600-1741282200@paradigms.foundation SUMMARY:Live Webinar on Safety tests in the clinical management of MS. DESCRIPTION:Safety Tests in the Clinical Management of MS \n\n\n\nJoin us for an insightful webinar exploring the critical role of safety tests in the clinical management of multiple sclerosis (MS). This session will provide an in-depth look at the latest advancements and practical applications of safety monitoring tools to enhance treatment outcomes and patient care. \n\n\n\nThis webinar is designed for neurologists\, trainees\, and healthcare professionals involved in MS care. Don’t miss this opportunity to gain valuable insights from leading experts in the field! \n\n\n\nRegister\n\n\n\nThis session will be delivered live on Zoom\, offering practical insights on the safety tests in clinical management of MS. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister to the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nWhy participate?\n\n\n\n\nLearn about an overview of essential safety tests for MS therapies.\n\n\n\nDiscover best practices for monitoring and mitigating treatment-related risks.\n\n\n\nListen to real-world case studies highlighting the importance of safety assessments.\n\n\n\n\nWho should join?\n\n\n\n\nNeurologists with an interest in multiple sclerosis treatments\n\n\n\nNeurologists in training \n\n\n\nNurses involved in MS patient care\n\n\n\nPatient representatives\n\n\n\n\nQuestions and comments\n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\nTechnology used\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nDate and time\n\n\n\nThe session will be held in English on Thursday\, 6th March 2025 from 16:30 to 17:30 CET. \n\n\n\nAbstract\n\n\n\nThe management of multiple sclerosis (MS) has evolved significantly with the advent of diverse therapeutic options\, each with distinct safety profiles. Ensuring optimal patient outcomes requires a robust framework for monitoring and mitigating potential treatment-related risks. This presentation explores the role of safety tests in the clinical management of MS\, focusing on their application across various treatment modalities. \n\n\n\nOur Speakers\n\n\n\n\n\n\n\nProf. Tjalf Ziemssen\n\n\n\n\n\n\n\nProfessor of Clinical Neuroscience at University Clinic Carl-Gustav Carus in Dresden  \n\n\n\n\nAbout Tjalf Ziemssen\n\n\n\n\n\n\n\n\nProf. Magd Zakaria\n\n\n\n\n\n\n\nHead of the Multiple Sclerosis Unit at the Ain Shams Specialized University Hospital  \n\n\n\n\nAbout Magd Zakaria\n\n\n\n\n\n\n\n\nModerator\n\n\n\nStefaan De Corte\, General Manager\, ParadigMS \n\n\n\nRegistration\n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n\nRegister now\n\n\n\n\nPlease note: this is a live webinar primarily for neurologists from Europe\, the Middle-East and North-Africa. Should you know a colleague from other regions who would be interested in the topic – kindly share the registration link and invite them to join.  The event is free of charge\, but registration is required. \n\n\n\nFunding\n\n\n\nThis webinar is organised with the financial support of Sandoz. Sandoz has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-safety-tests-in-the-clinical-management-of-ms/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/01/LAU-PROD-banner-live-webinar-sessions-250306-linkedin-2.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20241205T180000 DTEND;TZID=Europe/Paris:20241205T190000 DTSTAMP:20241205T144242Z CREATED:20241017T122625Z LAST-MODIFIED:20241205T144242Z UID:10004-1733421600-1733425200@paradigms.foundation SUMMARY:Live Webinar on MS Prognosis Scorecard: A Tool for Predicting Clinical Outcomes DESCRIPTION:Multiple sclerosis (MS) presents neurologists with a unique set of challenges\, as the disease’s clinical course is highly variable from patient to patient. This makes it difficult to predict progression\, tailor treatments\, and monitor outcomes effectively. This webinar introduces a prognosis tool designed to help clinicians navigate these complexities. \n\n\n\nThis webinar fits into the ongoing work ParadigMS supports on MS Prognosis. Visit our webpage for more information and to download the journal article and the prognosis tool itself. \n\n\n\n\nMS Prognosis in Practice\n\n\n\n\nRegister\n\n\n\nThis session will be delivered live on Zoom\, offering practical insights on using this checklist to improve patient care. Don’t miss this opportunity to enhance your understanding of personalized MS treatment strategies! \n\n\n\nRegister now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister to the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages. \n\n\n\nWhy participate?\n\n\n\n\nLearn a Practical Tool – Gain access to the MS Prognosis Scorecard\, a comprehensive checklist that simplifies the evaluation of clinical\, imaging\, and biomarker parameters to predict patient outcomes.\n\n\n\nEnhance Treatment Strategies – Discover how to use the scorecard to tailor treatment plans based on individual prognosis\, improving long-term outcomes for your MS patients.\n\n\n\nExpert Guidance – Benefit from the insights of leading neurologists who will share real-world examples and evidence-based recommendations on managing MS prognosis.\n\n\n\nStay Current – Keep up-to-date with the latest developments in MS prognosis tools and how they can be effectively integrated into daily practice.\n\n\n\nInteractive Session – Participate in live discussions and Q&A with experts\, gaining valuable feedback and ideas to apply in your own clinical work.\n\n\n\n\nWho should join?\n\n\n\n\nNeurologists with an interest in multiple sclerosis treatments\n\n\n\nNeurologists in training \n\n\n\nNurses involved in MS patient care\n\n\n\nPatient representatives\n\n\n\n\nQuestions and comments\n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\nTechnology used\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nDate and time\n\n\n\nThe session will be held in English on 5th December from 18:00 to 19:00 CET. \n\n\n\nAbstract\n\n\n\nThe clinical progression of multiple sclerosis (MS) is notoriously variable\, posing significant challenges for neurologists in treatment and monitoring. To address this\, a practical prognosis tool has been developed\, offering a checklist of key clinical\, imaging\, and biomarker parameters that are predictive of MS outcomes. This tool\, based on literature consensus and clinical experience\, aids neurologists in identifying critical “red flag” indicators at disease onset\, enabling more personalized and effective treatment strategies. \n\n\n\nOur Speaker\n\n\n\n\n\n\n\nProf. Bart Van Wijmeersch\n\n\n\nAssociate Professor of Neurology at the University of Hasselt  \n\n\n\n\nAbout Bart Van Wijmeersch\n\n\n\n\n \n\n\n\n\n\n\n\nModerator\n\n\n\nStefaan De Corte\, General Manager\, ParadigMS \n\n\n\nRegistration\n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n\nRegister now\n\n\n\n\nPlease note: this is a live webinar primarily for neurologists from Europe\, the Middle-East and North-Africa. Should you know a colleague from other regions who would be interested in the topic – kindly share the registration link and invite them to join.  The event is free of charge\, but registration is required. \n\n\n\nFunding\n\n\n\nThis webinar is funded with ParadigMS own funds. No other sponsors have been invited to support this webinar. URL:https://paradigms.foundation/event/ms-prognosis-scorecard-a-tool-for-predicting-clinical-outcomes/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/10/LAU-PROD-banner-live-webinar-sessions-241205-1200x627px-02.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20241031T190000 DTEND;TZID=Europe/Paris:20241031T194500 DTSTAMP:20241024T125139Z CREATED:20240805T130801Z LAST-MODIFIED:20241024T125139Z UID:9639-1730401200-1730403900@paradigms.foundation SUMMARY:ParadigMS Pre-MENACTRIMS Symposium 2024 DESCRIPTION:Join us at ParadigMS Pre-MENACTRIMS Symposium! \n\n\n\nThursday\, 31st October 2024\, Jeddah\, Saudi Arabia \n\n\n\nWe are thrilled to invite you to our upcoming symposium\, featuring the latest insights into multiple sclerosis (MS) management and treatment. The program includes an exploration of pregnancy and MS\, focusing on safety aspects and treatment modalities\, and strategies for managing MS in individuals aged 55 and above. Engage with experts during our live Q&A session and panel discussion\, providing an excellent platform for interactive learning and professional dialogue. Join us to stay at the forefront of MS research and care! \n\n\n\nFind out about the speakers and programme details: \n\n\n\nMSC2024-PreCongress-Paradigms-ProgramBookletDownload\n\n\n\nWith thanks to our sponsor\, who supports this event without any involvement in the elaboration of the presentations \n\n\n\n\n\n\n\nAccess the Merck knowledge forum at http://academe-ms.com/ \n\n\n\n \n\n\n\nVisit here for the registration: \n\n\n\n\nRegister today URL:https://paradigms.foundation/event/paradigms-pre-menactrims-symposium-2024/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/08/MSC2024-ParadigMS-EmailBlast.jpg ORGANIZER;CN="ParadigMS":MAILTO:secretariat@paradigms.foundation END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20241014T163000 DTEND;TZID=Europe/Paris:20241014T173000 DTSTAMP:20240910T120306Z CREATED:20240718T123546Z LAST-MODIFIED:20240910T120306Z UID:9562-1728923400-1728927000@paradigms.foundation SUMMARY:Live webinar on the use of generic\, biosimilar and non-biologic complex drugs for multiple sclerosis – Second edition – with German translation! DESCRIPTION:deutsch \n\n\n\n\n\n\n\n\n\nRegister \n\n\n\nJoin this webinar and familiarise yourself with the robust European regulatory processes and effective oversight for generic\, biosimilar\, and follow-on non-biologic complex drugs (NBCDs) of disease modifying therapies in multiple sclerosis. \n\n\n\nThis webinar will allow you to have informed conversations with your patients about the potential use of these agents and gives a detailed overview of the currently approved generic and biosimilar disease modifying therapies (DMTs). \n\n\n\nRegister now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister today\n\n\n\n\n\n\n\n\nLanguage \n\n\n\nThe session will be held in English. We offer simultaneous translation into German. Submit your questions or give your comments in English or German. \n\n\n\n\n\n\n\nWhy participate? \n\n\n\n\nLearn about the regulatory requirements for generics\, biosimilars and follow-on NBCD’s in Europe.\n\n\n\nUnderstand the clinical considerations for generics\, biosimilars and follow-on NBCD’s in multiple sclerosis.\n\n\n\nGet an overview of the currently approved generic and biosimilar disease modifying therapies for multiple sclerosis.\n\n\n\nHelp your patients make an informed decision.\n\n\n\n\n\n\n\n\nWho should join? \n\n\n\n\nNeurologists with an interest in multiple sclerosis treatments\n\n\n\nNeurologists in training \n\n\n\nNurses involved in MS patient care\n\n\n\nPatient representatives\n\n\n\n\n\n\n\n\nQuestions and comments \n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\n\n\n\n\nTechnology used \n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\n\n\n\n\nDate and time \n\n\n\nThe session will be held in English (with translation in German) on 14th October from 4:30 PM to 5:30 PM CEST. \n\n\n\n\n\n\n\nAbstract of the webinar \n\n\n\nBecause multiple sclerosis (MS) usually has an onset in early adulthood and is a progressive disease\, the economic burden is substantial\, and disease-modifying treatments (DMTs) constitute a large proportion of healthcare costs. The use of generic versions (of synthetic drugs)\, biosimilars (for biologics) or follow-on versions of non-biologic complex drugs (NBCDs) can reduce the overall cost of MS care and improve patient access. \n\n\n\nIn Europe\, there are robust regulatory processes and effective oversight for generic\, biosimilar and follow-on NBCDs of DMTs so that these agents can be considered interchangeable with the originator product. Physicians caring for patients with MS need to familiarise themselves with the evidence so that they can have informed conversations with their patients about the potential use of these agents. \n\n\n\n\n\n\n\nOUR SPEAKERS \n\n\n\n\n\n\n\nCelia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid and Professor of Neurology at the University Complutense\, Madrid\, Spain. \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest\, and Professor Oreja-Guevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO. As a principal investigator\, she has participated in more than 30c MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. \n\n\n\nBesides her clinical and research endeavors\, Professor Oreja-Guevara has held leadership roles in several neurology-focused organizations and academic societies\, such as the Demyelinating Diseases Group and the Neuroimaging Group of the Spanish Neurological Society .Professor Oreja-Guevara is also Co-Chair of the Multiple Sclerosis Panel of the European Academy of Neurology (EAN)\, and serves as an expert for the European Medicines Agency (EMA) and the Spanish Agency of Medicines and Medicinal Products\, highlighting her pivotal role in advancing neurology. \n\n\n\n Conflict if Interest Form – Celia Oreja-Guevara \n\n\n\n\n\n\n\nThomas Berger\, Professor of Neurology and Chair of the Dept. of Neurology at the Medical University of Vienna. \n\n\n\nThomas Berger\, MD\, MSc\, FEAN\, is Professor of Neurology and Chair of the Dept. of Neurology as well as Chair of the Comprehensive Center for Clinical Neurosciences & Mental Health at the Medical University of Vienna\, Austria.Scientific interests regard neuroimmunology\, especially inflammatory demyelinating CNS disorders with a dedicated focus on body-fluid and imaging biomarker research in multiple sclerosis\, NMOSD and MOGAD. \n\n\n\nConflict of Interest Form – Thomas Berger \n\n\n\n\n\n\n\nModerator \n\n\n\nStefaan De Corte\, General Manager\, ParadigMS \n\n\n\n\n\n\n\nREGISTRATION \n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n\nRegister here\n\n\n\n\nThe event is free of charge\, but registration is required. \n\n\n\nPlease note: this is a live webinar primarily for neurologists from Europe\, the Middle-East and North-Africa. Should you know a colleague from other regions who would be interested in the topic – kindly share the registration link and invite them to join.  The event is free of charge\, but registration is required. \n\n\n\n\n\n\n\nOUR SPONSOR \n\n\n\nThis webinar is organised with the financial support of Sandoz. Sandoz has not been involved in the elaboration of the presentations. \n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nLive-Webinar über den Einsatz von Generika\, Biosimilars und Arzneimitteln mit komplex zusammengesetzten Wirkstoffen bei Multipler Sklerose – Zweite Auflage – Mit deutscher Übersetzung!\n\n\n\n\n\nenglish \n\n\n\n\n\n\n\nAnmelden \n\n\n\nNehmen Sie an diesem Webinar teil und machen Sie sich vertraut mit den soliden europäischen Regulierungsverfahren und wirksamen Kontrollen bei Generika\, Biosimilars und Folgearzneimitteln mit komplex zusammengesetzten Wirkstoffen (NBCDs) für erkrankungsmodifizierende Therapien der Multiplen Sklerose. \n\n\n\nDieser Webinar wird Sie in die Lage versetzen\, im Hinblick auf den potentiellen Einsatz dieser Arzneimittel gut informiert in den Dialog mit Ihren Patienten zu treten. \n\n\n\nMelden Sie sich jetzt an\, um sich einen Platz zu sichern und am Wissensaustausch und an den Diskussionen teilzunehmen! \n\n\n\n\nHeute noch anmelden\n\n\n\n\n\n\n\n\nSprache \n\n\n\nDie Sitzung wird in englischer Sprache stattfinden. Wir stellen eine Simultanübersetzung ins Deutsche zur Verfügung. Unterbreiten Sie Ihre Fragen oder Ihre Diskussionsbeiträge auf Englisch oder Deutsch. Sie werden dann jeweils in die andere Sprache übersetzt werden. \n\n\n\n\n\n\n\nWarum teilnehmen? \n\n\n\n\nErfahren Sie mehr über die aufsichtsrechtlichen Auflagen für Generika\, Biosimilars und Folge-NBCDs in Europa.\n\n\n\nVerstehen Sie die klinischen Überlegungen bei Generika\, Biosimilars und Folge-NBCDs bei Multipler Sklerose.\n\n\n\nHelfen Sie Ihren Patienten dabei\, ihre Entscheidung mit Sachkenntnis zu treffen.\n\n\n\n\n\n\n\n\nWer sollte teilnehmen? \n\n\n\n\nAuf die Behandlung von MS spezialisierte Neurologen\n\n\n\nIn der Pflege von MS-Patienten tätige Krankenschwestern\n\n\n\nMS-Patienten und die sie pflegenden Personen\n\n\n\n\n\n\n\n\nFragen und Kommentare \n\n\n\nHaben Sie besondere Fragen und würden Sie sie gern diskutiert sehen? Schicken Sie sie jetzt an learning@paradigms.foundation\, damit die Redner sie in Ihren Vorträgen berücksichtigen können.  \n\n\n\nSie werden während des Webinars und der Frage-und-Antwort-Runde auch die Gelegenheit erhalten\, persönlich Fragen zu stellen und sich an den Diskussionen zu beteiligen. \n\n\n\n\n\n\n\nEingesetzte Technik \n\n\n\nDer Webinar wird über Zoom stattfinden. Die Verbindungsdaten werden Sie nach der Anmeldung erhalten. \n\n\n\n\n\n\n\nDatum und Uhrzeit \n\n\n\nDie Sitzung wird am 14. Oktober von 17.30 bis 17:30 MESZ in Englisch (mit Übersetzung ins Deutsche) stattfinden. \n\n\n\n\n\n\n\nDer Webinar kurz zusammengefasst \n\n\n\nDa die Multiple Sklerose (MS) im frühen Erwachsenenalter ausbricht und einen progressiven Krankheitsverlauf kennt\, ist sie mit einer erheblichen finanziellen Belastung verbunden\, wobei ein großer Teil der Gesundheitskosten auf erkrankungsmodifizierende Behandlungen (DMTs) entfällt. Der Einsatz generischer Versionen (oder synthetischer Arzneimittel)\, Biosimilars (für biologische Arzneien) oder Folgeversionen von Arzneimitteln mit komplex zusammengesetzten Wirkstoffen (NBCDs) ermöglicht eine Reduzierung der Gesamtkosten einer MS-Behandlung und eine gesteigerte Erschwinglichkeit für Patienten. \n\n\n\nIn Europa gibt es solide Regulierungsverfahren und wirksame Kontrollen für Generika\, Biosimilars und Folge-NBCDs oder DMTs\, sodass diese Arzneien als gleichwertig gegenüber dem Originalprodukt betrachtet werden können. Ärzte\, die MS-Patienten behandeln\, müssen sich mit den Gegebenheiten vertraut machen\, damit sie ihre Patienten gut informiert im potentiellen Einsatz dieses Arzneimittels beraten können. \n\n\n\n\n\n\n\nUNSERE REDNER \n\n\n\n\n\n\n\nCelia Oreja-Guevara ist Vize-Präsidentin für Neurologie und Leiterin des Centers für Multiple Sklerose an der Universitätsklinik San Carlos\, Madrid\, und Professorin für Neurologie an der Universität Complutense\, Madrid\, Spanien. \n\n\n\nNach Erwerb des Titels eines MD an der Universität Complutense\, Madrid\, erlangte Professor Oreja-Guevara einen Doktortitel in Neuroimmunologie am Max-Planck-Institut für Neurobiologie der Universität München\, München (Deutschland). Im Anschluss daran hat sie eine Facharztausbildung an der neurologischen Fakultät der Universität Bochum (Deutschland) und ein Postdoc-Stipendium in neurologischer Bildgebung an der Universitätsklinik San Raffaele in Mailand (Italien) absolviert. Sie war ebenfalls tätig an der Universität Düsseldorf (Deutschland) sowie an der Klinik Fuenlabrada und der Universitätsklinik La Paz\, beide in Madrid. \n\n\n\nProfessor Oreja-Guevaras Forschungsinteressen konzentrieren sich auf Familienplanung\, Menopause\, Korrelationen bei MS in der neurologischen Bildgebung und die Nutzung der optischen Kohärenztomographie. Neuromyelitis optica (NMO) zählt zu ihren sonstigen bevorzugten Therapiegebieten. Professor Oreja-Guevara ist aktiv an der Beurteilung neuer Arzneimittel für die Behandlung von MS und NMO beteiligt. Als Hauptprüferin hat sie an mehr als 30 klinischen Studien von MS-Arzneimitteln teilgenommen und leitet jetzt ParadigMS\, eine unabhängige internationale Vereinigung von Multiple-Sklerose-Experten ohne Erwerbszweck. \n\n\n\nNeben ihren Test- und Forschungsinitiativen hat Professor Oreja-Guevara leitende Positionen in mehreren der Neurologie gewidmeten Organisationen und akademischen Gesellschaften wie etwa der auf demyelinisierende Krankheiten und der auf neurologische Bildgebung spezialisierten Gruppe der spanischen Gesellschaft für Neurologie innegehabt. Professor Oreja-Guevara ist ebenfalls Vizepräsidentin des Gremiums für Multiple Sklerose der Europäischen Akademie für Neurologie (EAN) und arbeitet als Expertin für die Europäische Arzneimittelagentur (EMA) sowie für die Spanische Agentur für Arzneimittel und Medizinprodukte\, was ihre Schlüsselrolle bei der Förderung der Neurologie unterstreicht. \n\n\n\nInteressenkonflikte-Formular – Celia Oreja-Guevara \n\n\n\n\n\n\n\nThomas Berger\, Professor für Neurologie und Inhaber des Lehrstuhls für Neurologie an der Medizinischen Universität Wien. \n\n\n\nThomas Berger\, MD\, MSc\, FEAN\, ist Professor für Neurologie und Inhaber des Lehrstuhls für Neurologie und Leiter des Comprehensive Center for Clinical Neurosciences & Mental Health an der Medizinischen Universität Wien\, Österreich.Sein wissenschaftliches Interesse gilt der Neuroimmunologie\, insbesondere entzündlichen demyelinisierenden Erkrankungen des zentralen Nervensystems mit besonderem Schwerpunkt auf die Erforschung von Körperflüssigkeiten und biologischen Markern bei Multipler Sklerose\, NMOSD (Neuromyelitis-optica-Spektrum-Erkrankungen) und MOGAD (Myelin oligodendrocyte glycoprotein antibody disease – MOG-Antikörpererkrankung). \n\n\n\nInteressenkonflikte-Formular – Thomas Berger \n\n\n\n\n\n\n\nModerator \n\n\n\nStefaan De Corte\, General Manager\, ParadigMS \n\n\n\n\n\n\n\nANMELDUNG \n\n\n\nEine Anmeldung ist notwendig und durch Klicken auf die Schaltfläche oben auf dieser Seite oder hier möglich: \n\n\n\n\nAnmeldung\n\n\n\n\nDie Teilnahme an der Veranstaltung ist kostenlos\, aber anmeldepflichtig. \n\n\n\nBeachten Sie bitte: Dies ist ein Live-Webinar\, der sich vorrangig an Neurologen aus Europa\, Nahost und Nordafrika richtet. Sollten Sie einen Kollegen aus anderen Regionen kennen\, die sich für dieses Thema interessieren würde\, geben Sie freundlicherweise den Anmeldelink durch und laden Sie ihn zum Webinar ein.  \n\n\n\n\n\n\n\nUNSER SPONSOR \n\n\n\nDieser Webinar wird mit finanzieller Unterstützung von Sandoz veranstaltet. Sandoz ist an der Ausarbeitung der Vorträge nicht beteiligt. URL:https://paradigms.foundation/event/live-webinar-on-the-use-of-generic-biosimilar-and-non-biologic-complex-drugs-for-multiple-sclerosis/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/07/LAU-PROD-banner-live-webinar-sessions-1200x627px-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20240907T090000 DTEND;TZID=Europe/Paris:20240907T120000 DTSTAMP:20241105T135903Z CREATED:20240719T151649Z LAST-MODIFIED:20241105T135903Z UID:9624-1725699600-1725710400@paradigms.foundation SUMMARY:Expert Meeting 7th September 2024 DESCRIPTION:On Saturday\, 7th September\, ParadigMS will convene an Expert Meeting in Budapest\, assembling top specialists in multiple sclerosis to review and discuss educational materials on MS treatment and care. \n\n\n\nThe detailed agenda of the meeting: \n\n\n\n\nNEW TOPIC: Consensus quality indicators for the monitoring of multiple sclerosis (Tjalf Ziemssen)\n\n\n\nFINAL PRESENTATION: Beyond EDSS: How to monitor disease progression in multiple sclerosis (Bart Van Wijmeersch)\n\n\n\nNEW TOPIC: Biomarkers (Florian Deisenhammer and Andrew Chan)\n\n\n\nNEW TOPIC: NMO/MOGAD: Diagnosis and Treatment (Celia Oreja-Guevara and Melinda Magyari) \n\n\n\nFINAL PRESENTATION: Generics\, Biosimilars and NBCDs in the Treatment of MS (Thomas Berger (not present) and Celia Oreja-Guevara)\n\n\n\nUpdate on Project: Prognosis Factors in MS (Sofie Aerts)\n\n\n\nDiscussion on future topics and articles status (Celia Oreja-Guevara) \n\n\n\n\nThe final presentations will be shared on our platform shortly. \n\n\n\n\n\n\nWith thanks to our sponsor\, who supports this event without any involvement in the elaboration of the presentations. URL:https://paradigms.foundation/event/expert-meeting-7th-september-2024/ ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2024/09/Experts-Budapest-.png ORGANIZER;CN="ParadigMS":MAILTO:secretariat@paradigms.foundation END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20240629T080000 DTEND;TZID=Europe/Paris:20240702T200000 DTSTAMP:20240522T142016Z CREATED:20240522T141930Z LAST-MODIFIED:20240522T142016Z UID:9104-1719648000-1719950400@paradigms.foundation SUMMARY:ParadigMS presence at EAN DESCRIPTION:The 10th Congress of the European Academy of Neurology (EAN) will take place in Helsinki\, Finland (and online) from 29 June to 2 July 2024. \n\n\n\nThe overarching theme for EAN 2024 is ‘Neuromodulation: advances and opportunities in neurological diseases’\, which will be the focus of several sessions\, with something for every category of participant\, from trainees to specialists\, for both clinicians and scientists.       \n\n\n\nThe congress programme will be bursting with Symposia\, Workshops\, Teaching Sessions\, and much more\, including some exciting named Lectures from top-class line-up of speakers \n\n\n\nParadigMS is excited to join this prestigious event\, where we will have the possibility to showcase our impactful learning initiatives and foster awareness within the neurology community. \n\n\n\nCheck the official website for more information! \n\n\n\n\nEVENT WEBSITE URL:https://paradigms.foundation/event/paradigms-presence-at-ean/ LOCATION:Messukeskus Expo\, Messuaukio 1\, 00520\, Finland ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/05/LAU-PROD-banner-general-EAN-Congress-2024-1200x600-002_WEBSITE-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20240611T153000 DTEND;TZID=Europe/Paris:20240611T163000 DTSTAMP:20240521T144907Z CREATED:20240404T124944Z LAST-MODIFIED:20240521T144907Z UID:8839-1718119800-1718123400@paradigms.foundation SUMMARY:Live webinar on the use of generic\, biosimilar and non-biologic complex drugs for multiple sclerosis DESCRIPTION:Register now! \n\n\n\nJoin this valuable and instructive webinar! \n\n\n\nFamiliarise yourself with the robust European regulatory processes and effective oversight for generic\, biosimilar\, and follow-on non-biologic complex drugs (NBCDs) of disease modifying therapies in multiple sclerosis that allow you to have informed conversations with your patients about the potential use of these agents. \n\n\n\nRegister now to gain insights from experts and ultimately optimize MS treatment strategies and improve patient outcomes! \n\n\n\n\nREGISTER\n\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nThe session will be held in English (translation in Spanish) on June 11th from 3:30 PM to 4:30 PM CEST. \n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation \n\n\n\n\n\n\n\nWhy participate? \n\n\n\n\n\nLearn about the regulatory requirements for generics\, biosimilars and follow-on NBCD’s in Europe.\n\n\n\nUnderstand the clinical considerations for generics\, biosimilars and follow-on NBCD’s in multiple sclerosis. \n\n\n\n\n\nWho should join? \n\n\n\nNeurologists who deal with multiple sclerosis (MS) treatment and management. Nurses working in the field of multiple sclerosis and patient representatives are also welcome to register. \n\n\n\n\n\n\n\nAbstract \n\n\n\nBecause multiple sclerosis (MS) usually has an onset in early adulthood and is a progressive disease\, the economic burden is substantial\, and disease-modifying treatments (DMTs) constitute a large proportion of healthcare costs. The use of generic versions (of synthetic drugs)\, biosimilars (for biologics) or follow-on versions of non-biologic complex drugs (NBCDs) can reduce the overall cost of MS care and improve patient access. \n\n\n\nIn Europe\, there are robust regulatory processes and effective oversight for generic\, biosimilar and follow-on NBCDs of DMTs so that these agents can be considered interchangeable with the originator product. Physicians caring for patients with MS need to familiarise themselves with the evidence so that they can have informed conversations with their patients about the potential use of these agents. \n\n\n\n\n\n\n\nOUR SPEAKERS \n\n\n\n\n\n\n\nCelia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid and Professor of Neurology at the University Complutense\, Madrid\, Spain. \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest\, and Professor Oreja-Guevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO. As a principal investigator\, she has participated in more than 30c MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. \n\n\n\nBesides her clinical and research endeavors\, Professor Oreja-Guevara has held leadership roles in several neurology-focused organizations and academic societies\, such as the Demyelinating Diseases Group and the Neuroimaging Group of the Spanish Neurological Society. Professor Oreja-Guevara is also Co-Chair of the Multiple Sclerosis Panel of the European Academy of Neurology (EAN)\, and serves as an expert for the European Medicines Agency (EMA) and the Spanish Agency of Medicines and Medicinal Products\, highlighting her pivotal role in advancing neurology. \n\n\n\nConflict of Interest Form – Celia Oreja-Guevara\n\n\n\n\n\n\n\nThomas Berger\, Professor of Neurology and Chair of the Dept. of Neurology at the Medical University of Vienna. \n\n\n\nThomas Berger\, MD\, MSc\, FEAN\, is Professor of Neurology and Chair of the Dept. of Neurology as well as Chair of the Comprehensive Center for Clinical Neurosciences & Mental Health at the Medical University of Vienna\, Austria.Scientific interests regard neuroimmunology\, especially inflammatory demyelinating CNS disorders with a dedicated focus on body-fluid and imaging biomarker research in multiple sclerosis\, NMOSD and MOGAD. \n\n\n\nConflict of Interest Form – Thomas Berger\n\n\n\nModerator: Stefaan De Corte\, General Manager\, ParadigMS \n\n\n\n\n\n\n\nREGISTRATION \n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n\nREGISTER\n\n\n\n\n\n\nPlease note: this is a live webinar primarily for neurologists from Europe\, the Middle-East and North-Africa. Should you not fit this category and should we reach maximum capacity (100)\, we might cancel your registration. \n\n\n\n\n\n\n\nOUR SPONSOR \n\n\n\nThis webinar is organised with the financial support of Sandoz. Sandoz was not involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-the-use-of-generics-biosimilars-and-nbcds-for-multiple-sclerosis/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/05/LAU-PROD-banner-live-webinar-sessions-1200x627px.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20240328T173000 DTEND;TZID=Europe/Paris:20240328T223000 DTSTAMP:20240415T143402Z CREATED:20240105T104200Z LAST-MODIFIED:20240415T143402Z UID:7921-1711647000-1711665000@paradigms.foundation SUMMARY:ParadigMS 9th Belgian Symposium 2024 DESCRIPTION:ParadigMS Ninth Belgian Symposium promises to be a clinically relevant learning experience\, set against the backdrop of a friendly dinner environment. The event will feature engaging keynotes and clinical case discussions\, providing a unique opportunity for insightful dialogue and professional growth. \n\n\n\nProf. Romain Marignier will share expertise on  \n\n\n\n‘Differential Diagnosis in Multiple Sclerosis\, NMO-SD\, and MOGAD’ \n\n\n\noffering valuable insights that promise to enrich your understanding of these conditions. \n\n\n\nAdditionally\, distinguished clinical biologists\, Mrs. Laurence Lutteri from CHU Liège and Dr. Matthijs Oyaert from UZ Gent\, will present the various diagnostic tests available for MS\, NMO-SD\, and MOGAD. \n\n\n\nMrs. Lutteri will lead the lecture titled ‘Advances in Clinical Techniques for CNS Inflammatory Diseases‘ in La Hulpe\, and Dr. Oyaert will lead the lecture titled ‘Antibodies in Focus: Advancements in Diagnosing NMO and MOG-related CNS Disorders‘ in Ghent. Their presentations will draw from their extensive hospital experiences\, providing a comprehensive overview of the current diagnostic landscape. \n\n\n\nOur Symposium is helmed by Prof. Bart Van Wijmeersch from UHasselt as the Symposium Chair. Prof. Dominique Dive from CHU Liège and Prof. Guy Laureys from UZ Gent serve as our esteemed Programme Chairs\, facilitating the clinical case discussions. These discussions\, thoughtfully introduced and moderated\, will unfold at each table\, allowing for dynamic interaction and collaborative exploration of challenging cases. \n\n\n\n\n\n\n\n\n\n\nBuy Tickets on Eventbrite\n\nRegister\n\n\n\n\n\n\n\n\n\n\n\nProgrammeSpeakers and abstractsSponsors\n\nMarch 7th\, La HulpeMarch 28th\, Ghent17:45 – 19:00 Registration and welcome drinks. NetworkingRegistration and welcome drinks. Networking18:15 – 18:45Sponsored break-out AlexionSponsored break-out Alexion19:00 – 19:45Welcome by Mr. Stefaan De Corte\, ParadigMS Manager and by Programme Chair\, Prof. Dominique Dive (CHU Liège) & Main lecture on Differential Diagnosis in MS\, NMO-SD and MOGAD by Prof. Romain Marignier (CHU Lyon)Welcome by Symposium Chair\, Prof. Bart Van Wijmeersch and Programme Chair\, Prof. Guy Laureys (UZGent) & Main lecture on Differential Diagnosis in MS\, NMO-SD and MOGAD by Prof. Romain Marignier (CHU Lyon)19:45 – 20:10First course. Clinical case discussions.First course. Clinical case discussions.20:10 – 20:40Lecture on Advances in Clinical Techniques for CNS Inflammatory Diseases by Dr. Laurence Lutteri (CHU Liège) & Introduction to clinical cases by the Programme Chair and case presentersLecture on Antibodies in Focus: Advancements in Diagnosing NMO and MOG-related CNS Disorders by Dr. Matthijs Oyaert (UZGent) & Introduction to clinical cases by the Programme Chair and case presenters 20:40 – 21:15Main course. Facilitated case presentations and discussions. Main course. Facilitated case presentations and discussions. 21:15 – 21:45Continued clinical case discussion. Conclusions by Programme ChairsContinued clinical case discussion. Conclusions by Programme Chairs21:45 – 22:30Dessert. NetworkingDessert. Networking\n\n\n\n\n\n\n\n\n\nProf. Romain MARIGNIER – MD\, PhD \n\n\n\nPr. Romain Marignier is a neurologist (MD)\, professor in the Neurological Hospital of Lyon\, France. His field of expertise are the neuro-inflammatory disorders of the central nervous system with a specific interest on rare disorders\, namely neuromyelitis optica spectrum disorders (NMOSD) and MOG-Ab associated diseases (MOGAD). Pr Marignier is the coordinator of the French nationwide NMO and MOGAD cohorts and biobanks\, NOMADMUS\, set up in 2010 that includes all the French clinical experts in neuro-inflammatory disorders. Through NOMADMUS\, Pr Marignier provided breakthrough insights in the topic regarding clinical characterization\, management\, and treatment of NMOSD and MOGAD\, supported by major publication in high-profile journals. \n\n\n\nSince 2017\, Pr Marignier is the head of the French referral center for rare inflammatory disorder of the central nervous system (MIRCEM)\, providing expertise on diagnosis and management of NMOSD and MOGAD for both patients and clinicians. \n\n\n\nFinally\, Pr. Marignier achieved a PhD on basic neurosciences in 2011 at Claude Bernard University Lyon 1 on the role of auto-antibodies in NMOSD and related diseases. He actually performs his research at INSERM unit 1028 in Lyon Neuroscience Research Centre (CRNL) on: 1. The pathophysiology of auto antibody- mediated disorders of the central nervous system with in vitro\, ex vivo and animal models; 2. The development of new strategies to optimise detection of auto-antibodies (anti-AQP4\, anti-MOG\, anti-GFAP) for diagnosis and prognosis purpose (immunohistochemistry\, flow cytometry). \n\n\n\nAbstract of talk \n\n\n\nIn the past 20 years\, the concept of antibody mediated demyelinating disorders have emerged. These diseases\, namely Aquaporin-4 (AQP4) positive neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte (MOG)- antibody associated disease (MOGAD)\, share common features with multiple sclerosis\, but are fundamentally different in terms of pathophysiology\, disease course and treatment. In this lecture we will provide a clinical\, biological and imaging description of these two entities\, and propose a focus on the features that helps to differentiate in between these conditions. \n\n\n\nLearning objectives: \n\n\n\n\nto know the diagnostic criteria for NMOSD and MOGAD as compared to MS\n\n\n\n\n\nto identify the situation when to search for AQP4-IgG and/or MOG-IgG \n\n\n\n\n\nto know the principles of attack and preventive therapies of NMOSD and MOGAD\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Laurence LUTTERI \n\n\n\nDr. Laurence Lutteri has a master in pharmacy and a specialization in laboratory medicine.  \n\n\n\nShe heads the auto-immunity and specialized biochemistry laboratories in the department of clinical chemistry at the University Hospital of Liège. \n\n\n\nShe collaborates in different projects about connective tissue diseases with rheumatologists\, with neurologists for the diagnosis of multiple sclerosis and other inflammatory diseases and also with hematologists for the diagnosis and the follow-up of monoclonal gammopathies. \n\n\n\nImmunofluorescence\, Elisa\, immunodots\,…are the different methods used in her auto-immunity laboratory and electrophoresis\, immunofixation\, turbidimetry\, nephelometry and a lot of different manual techniques in the biochemistry laboratory. \n\n\n\nAbstract of talk \n\n\n\nVarious techniques are used in clinical biology laboratories to diagnose inflammatory diseases of the central nervous system (CNS). Detection of cerebrospinal fluid (CSF)-restricted oligoclonal bands (OCB) has been used for many years to diagnose multiple sclerosis. More recently\, determination of kappa free light chains in CSF/serum has been developed and offers some advantages : fast\, reliable\, rater-independent\, quantitative results – over OCB technique. \n\n\n\nIn the differential diagnosis of demyelinating disorders of the CNS\, the laboratory’s first-line tests are antibodies targeting aquaporin-4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) autoantibodies on transfected cells (fixed Cell Based Assays (CBA)). In the event of clinically inconsistent results\, flow cytometric analysis (live CBA) would show better performance. \n\n\n\n\n\n\n\n\n\n\n\nDr. Matthijs OYAERT \n\n\n\nDr. Matthijs Oyaert graduated as a master in drug development (pharmacy) in 2011 and master in  clinical biology in 2016 at the KU Leuven and started working as a clinical biologist at the clinical laboratory of the Ghent University hospital. In the laboratory of clinical chemistry and hematology\, he is responsible for a broad variety of (automated) routine clinical chemistry and immunochemistry tests and urinary test strip and particle analysis. In addition\, he is involved in the laboratory diagnosis of auto-immune and neuroinflammatory diseases. \n\n\n\nDuring the first years\, he obtained his PhD in 2021 entitled “New developments in the laboratory diagnosis of urinary tract pathology” at the Ghent University. Besides his activity in the Sciensano expert group of TDM\, chemistry and immunochemistry and member of the European Federation of Laboratory Medicine (EFLM)\, he is an active Member of the current Royal Belgian Society of Laboratory Medicine (RBSLM) board. \n\n\n\nSince 2021\, he is involved in the EFLM Task and Finish Group on Urinalysis under the supervision of Prof. Dr. Timo Kouri. \n\n\n\nAbstract of talk \n\n\n\nOver the last decade\, knowledge of antibodies linked to inflammatory disorders of the central nervous system\, including forms of neuromyelitis optica (NMO) spectrum disorders\, acute disseminated encephalomyelitis (ADEM)\, optic neuritis and transverse myelitis\, has significantly reshaped the landscape of the diagnosis and clinical care. Notably\, highly specific antibody assays have become an integral part of clinical decision making and include antibodies directed against the aquaporin-4 and anti–myelin oligodendrocyte glycoprotein (MOG). \n\n\n\nVarious assays have been developed to identify and quantify anti-MOG. First generation assays\, including enzyme-linked immunosorbent assays (ELISA) and western blots\, are characterized by a poor sensitivity and specificity. To tackle this disadvantage\, during the past 10 years\, cell-based assays (CBA) in which the recombinant antigen is expressed in its natural confirmation have been developed. Immunofluorescence or flow cytometry is subsequently employed to visualize and quantify antibody binding. Both live and fixed cell CBAs are utilized\, offering enhanced sensitivity and specificity. Moreover\, techniques such as immunoprecipitation provide complementary means for MOG antibody detection\, allowing for confirmation and characterization of MOG antibody subtypes. The selection of an appropriate assay depends on the diagnostic performance\, as well as the laboratory’s technical capabilities. \n\n\n\nDuring this presentation\, the different assays for the detection of anti-NMO and anti-MOG antibodies will be discussed\, including their performance in the different patient populations. Although a lot of progress has already been made in the development\, further efforts need to be undertaken to standardize the different assays. \n\n\n\n\n\nThis valuable learning experience is made possible through the generous support of our sponsors\, whom we sincerely thank. It’s important to note that while our sponsors contribute to the success of the event\, they have no involvement or influence on the learning content itself. We remain committed to providing an unbiased and enriching educational experience for all participants. \n\n\n\nPlatinum \n\n\n\n\n\n\n\nGold \n\n\n\n\n\n\n\n\n\nFAQSponsored breakoutLocations\n\n\nWhen and where is the event taking place?\n\nThe first edition of the ParadigMS Belgian Symposium will take place on Thursday\, 7th of March 2024 at Dolce La Hulpe Hotel in La Hulpe. The second edition of the ParadigMS Belgian Symposium will take place on Thursday\, 28th of March 2024 at Van der Valk Hotel in Ghent. \n\n\n\n\n\nHow can I register for the event?\n\nSimply click on REGISTER button you can see above this section and then select your preferred event session and sponsored break-out session. \n\n\n\n\n\nIs there a registration fee?\n\nNo\, this learning experience is offered for free to neurologists across Belgium\, Luxembourg and the Netherlands thanks to the support of the sponsors. Registration is mandatory and seats are limited. \n\n\n\n\n\nWill there be any networking opportunities?\n\nThe seated dinner environment will offer plenty of networking opportunities\, in addition to the Welcome drinks and Desert networking. \n\n\n\n\n\nWill there be a sponsor breakout?\n\nYes\, please refer to the programme for more details. \n\n\n\n\n\nAre there any accommodations nearby?\n\nBoth venues\, located within hotels\, offer convenient accommodation options for participants.\n\n\n\n\n\nIs there parking available at the venue?\n\nBoth venues provide free parking for participants. Please check the Location tab.\n\n\n\n\n\nCan I bring a guest?\n\nYou can register up to 5 persons per session\, if they are also healthcare professionals with a focus on neurology.\n\n\n\n\n\nHow can I get updates or notifications about the event?\n\nStay connected with all updates and news by subscribing to the ParadigMS Foundation webpage: https://paradigms.foundation/ \n\n\n\n\n\nIs there a dress code for the event?\n\nWe recommend wearing smart casual attire.\n\n\n\n\n\nWill there be food and beverages provided?\n\nYes\, we provide a three-course dinner with a variety of drinks. \n\n\n\n\n\nWhat if I need to cancel my registration?\n\nIf you need to cancel your registration\, please send a message to learning@paradigms.foundation.\n\n\n\n\n\nHow can I become a sponsor of the event?\n\nIf you wish to become a sponsor of this event\, please send a message to learning@paradigms.foundation. \n\n\n\n\n\nWho can I contact for additional information?\n\nIf you have any questions or need further information about either of the two learning experiences\, please feel free to reach out to us at learning@paradigms.foundation. \n\n\n\n\n\nWhat if organisers need to cancel the event?\n\nThe Symposium is organised by LAUREA Group BV in collaboration with ParadigMS Foundation. The organiser reserves the right to cancel the event at any time due to unforeseen circumstances. In that case\, registrants will be notified by email and no compensation can be claimed. \n\n\n\n\n\nWill this symposium be live streamed?\n\n No\, the two live sessions of the Symposium are not live streamed and available only for onsite participants.\n\n\n\n\n\nWhom can register for one of the sessions?\n\nThe Symposium is open for neurologists\, residents and neuroscience nurses from Belgium\, Luxembourg and the Netherlands. If you do not fall within this category\, please ask for prior approval to the ParadigMS secretariat before registering. If you register without prior approval and are not within the welcomed categories\, the organisers reserve the right to cancel your registration. In case of cancellation\, you will be notified. You can contact us via learning@paradigms.foundation.\n\n\n\n\n\nCan I join both the session in La Hulpe and in Ghent?\n\nNo\, in principle it is not allowed to join both sessions. Please note that both sessions have a very similar programme and are organised in a different language. Should you wish to join both sessions\, please contact us prior to your registration. In case of cancellation\, you will be notified. You can contact us via learning@paradigms.foundation.\n\n\n\n\n\nWill there be a written report from the sessions?\n\nYes\, the ParadigMS Secretariat is planning to have a medical writer on site who will be tasked with producing a written report from both sessions.\n\n\n\n\n\nWill any of the sessions be recorded on video for later viewing?\n\nYes\, the keynote of Prof. Marignier in Ghent will be video and audio recorded and will be made available on ParadigMS.foundation. You will need to create a Member account to have access to the recording (conditions to join as a member apply). \n\n\n\n\n\n\n\n\nKeynote \n\n\n\n‘Precision medicine: targeting complement in the prevention of NMOSD relapses‘ \n\n\n\n\n\n\n\nAbstract of talk \n\n\n\nData presented at the meeting will feature insights from Alexion’s complement portfolio illustrating the critical role of C5 inhibition in treating AQP4 Ab+ NMOSD and significantly reducing the risk of relapses\, including data from the phase III trial with the long-acting C5 complement inhibitor ravulizumab. \n\n\n\n\n\n\n\nSpeakers \n\n\n\n\n\n\n\nProf. Dr. Dominique Dive from CHU Liège \n\n\n\nMarch 7th\, La Hulpe\, 18:15-18:45 CET \n\n\n\nProf. Dr. Dominique Dive has been working on dysimmune diseases of the central nervous system for more than 30 years; it was the development of evoked potentials that led him to focus on multiple sclerosis\, and particularly paediatric multiple sclerosis.  He is a member of several national and international associations. \n\n\n\n\n\n\n\nProf. Dr. Guy Laureys from UZ Gent \n\n\n\nMarch 28th\, Ghent\, 18:15-18:45 CET \n\n\n\nProf. Dr. Guy Laureys is the head of the neuroinflammatory care unit at the UZ Ghent Department of neurology. As such he is involved in research\, education and treatment of neuroinflammatory disorders. As a member of the ERN-RITA the neuroinflammatory care unit is a reference centre for rare neuroimmunological disorders such as NMO\, MOGAD\, Susac and autoimmune encephalitis. \n\n\n\n\n\n\n\nPracticalities \n\n\n\nBefore joining the sponsored breakout session\, please stop by the Welcome and Registration desk to collect your badge. You will be guided to the breakout room reserved for each session. \n\n\n\n\n\nParadigMS Ninth Belgian Symposium – 1st edition\, March 7\, 2024 \n\n\n\nLocation: Dolce by Wyndham La Hulpe Brussels \n\n\n\nAddress: Chau. de Bruxelles 135\, 1310 La Hulpe \n\n\n\n\nParking: Participants can park for free at Dolce La Hulpe Hotel’s two parking spaces (P1 – charging stations available\, and P2)\, and then use the hotel main entrance (the blue bubble in the picture). \n\n\n\n\nRegistration and welcome desk: Participants can collect their badges at the Registration and Welcome desk\, located right after the main entrance. \n\n\n\n\n\n\n\nParadigMS Ninth Belgian Symposium – 2nd edition\, March 28\, 2024 \n\n\n\nLocation: Van der Valk Hotel Gent \n\n\n\nAddress: Akkerhage 10\, 9000 Gent \n\n\n\n\nParking: Participants can park for free at Van der Valk Hotel Gent’s underground parking spaces (H1\, with parking ticket)\, above-ground parking spaces (H2\, with parking ticket) but also in a second parking lot\, namely the Springpress parking lot\, which is the building opposite the hotel (H3\, no parking ticket). \n\n\n\n\nEntrance: Please use the main entrance and ascend the centrally located circular staircase to reach the first floor\, where the symposium takes place. \n\n\n\nRegistration and welcome desk: Upon reaching the first floor\, kindly stop to acquire your badge from our registration and welcome desk. URL:https://paradigms.foundation/event/paradigms-belgian-symposium-2024/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/01/LAU-PROD-banner-general-9th-Symposium-1080x655-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20240301T080000 DTEND;TZID=Europe/Paris:20240302T170000 DTSTAMP:20240829T153453Z CREATED:20240829T153453Z LAST-MODIFIED:20240829T153453Z UID:9787-1709280000-1709398800@paradigms.foundation SUMMARY:INIC 2024 DESCRIPTION:Held from March 1-2\, 2024\, in Riyadh\, Saudi Arabia\, INIC 2024 is the first-ever scientific conference in the region focused on neuroimmunology. Esteemed local and international speakers will deliver cutting-edge presentations aimed at educating both professionals and non-professionals on critical topics such as Multiple Sclerosis (MS) and neuroimmunological diseases. Through these sessions\, the conference is seeking to improve early diagnosis\, enhance interventions\, and empower patients with knowledge and advocacy. \n\n\n\nParadigMS experts are playing a significant role\, presenting on advancements in MS treatments and the integration of AI in personalized medicine. Notable topics include novel therapies targeting microglial cells\, updates on stem cell transplantation for MS\, and the evolving understanding of MS as a continuum of chronic inflammation and disease progression. \n\n\n\nThis groundbreaking conference provides a unique platform for advancing the understanding and management of neuroimmunological diseases\, ultimately aiming to improve patient outcomes across the region. \n\n\n\nThe presentations will be recorded and shared on our platform. URL:https://paradigms.foundation/event/inic-2024/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/08/INIC-24.jpg END:VEVENT END:VCALENDAR